<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by BIOS on Medium]]></title>
        <description><![CDATA[Stories by BIOS on Medium]]></description>
        <link>https://medium.com/@bioscommunity?source=rss-183f327fce8c------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*rKKPCIvBDOXZkAYCyb4zRg.png</url>
            <title>Stories by BIOS on Medium</title>
            <link>https://medium.com/@bioscommunity?source=rss-183f327fce8c------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Mon, 16 Nov 2026 08:15:56 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@bioscommunity/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[10 Questions w/ Joel Dudley — Partner @ Innovation Endeavors]]></title>
            <link>https://medium.com/bios-community/10-questions-w-joel-dudley-partner-innovation-endeavors-2a8973a524fe?source=rss-183f327fce8c------2</link>
            <guid isPermaLink="false">https://medium.com/p/2a8973a524fe</guid>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[biotech]]></category>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[biology]]></category>
            <category><![CDATA[science]]></category>
            <dc:creator><![CDATA[BIOS]]></dc:creator>
            <pubDate>Thu, 24 Aug 2023 19:49:59 GMT</pubDate>
            <atom:updated>2023-08-24T19:49:59.623Z</atom:updated>
            <content:encoded><![CDATA[<h3>10 Questions w/ Joel Dudley — Partner @ Innovation Endeavors</h3><p><a href="https://www.bios.community/"><strong>BIOS</strong></a><strong>: </strong>Nucleus of Life Science Innovation 🚀</p><p><strong>JOBS</strong></p><ul><li><strong>BIOS Talent: </strong>Find Jobs @ Breakout TechBio Startups — <a href="https://jobs.bios.community/companies"><strong><em>Search Jobs</em></strong></a> 🚀</li><li><strong>Post Jobs: </strong>Add Your Startup to BIOS Talent — <a href="https://docs.google.com/forms/d/e/1FAIpQLScR_bLlCQ7Ie6bJ_HZ_dJ_LmuV3TsDEi-aNDC8N9GPz6psk1Q/viewform"><strong><em>Post Now</em></strong></a><strong><em> </em></strong>🎉</li><li><strong>Students:</strong> <a href="https://www.alix.vc/students">Join Alix Ventures Fellowship</a> — <a href="https://docs.google.com/forms/d/e/1FAIpQLSckliaB67e-W2o9cmSbRNPLKrBBmtAx_S6CiFufc6QwHSCWSg/viewform"><strong>J<em>oin Now</em></strong></a><em> </em>🧬</li><li><strong>BIOS Contributor:</strong><em> </em><a href="https://medium.com/bios-community/write-for-bios-guest-contributor-aff9fbe6e1e">Share Your Thought Leadership</a> — <a href="https://docs.google.com/forms/d/e/1FAIpQLSdGPtCdigoAu0ePKvsgcq08qPwRFWkKrHOjIQe7nCP5II_Xeg/viewform"><strong><em>Join Now</em></strong></a></li></ul><p><strong>CONTENT &amp; COMMUNITY</strong></p><ul><li><strong>BIOS Daily:</strong> Join <em>25K+</em> Subscribers Following TechBio — <a href="https://www.bios.community/content"><strong><em>Sign Up</em></strong></a><em> </em>🔥</li><li><strong>BIOS Insider: </strong>Premium TechBio Thought Leadership — <a href="https://bioscommunity.substack.com/"><strong><em>Sign Up</em></strong></a><strong> </strong>✨</li><li><strong>BIOS Commons: </strong><a href="https://medium.com/bios-community/introducing-bios-fostering-early-stage-healthcare-life-sciences-innovation-78c11dd57fff">World’s Largest <em>#TechBio </em>Community</a> — <a href="https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform"><strong><em>Join Now</em></strong></a><strong><em> </em></strong>🎉</li></ul><p><strong>INVEST</strong></p><ul><li><strong>BIOS Angels:</strong> <a href="https://medium.com/bios-community/introducing-bios-angels-worlds-1st-techbio-angel-syndicate-5faec24d8439">1st TechBio Angel Investing Syndicate </a>— <a href="https://docs.google.com/forms/d/e/1FAIpQLSe_0k-Ehi2uzTa_geqDm_B9kuRVWNyrvWSU7ch_5hqEKMoahg/viewform"><strong><em>Join Now</em></strong></a><strong><em> </em></strong>🌟</li><li><strong>Alix Limited: </strong>Invest in Breakout TechBio Startups — <a href="https://docs.google.com/forms/d/e/1FAIpQLSfqKG3fZOcXTtZTwKEk3wOvN0CyIIUBZkn-FFf5JhRHE1zW0Q/viewform"><strong><em>Learn More</em></strong></a><strong><em> </em></strong>🧠</li></ul><p><strong>By:</strong></p><p><a href="https://www.alix.vc/"><strong>Alix Ventures</strong></a><strong>: </strong>Supporting Early Stage Life Science Startups Engineering Biology to Drive Radical Advances in Human Health</p><p><strong>Calling All Innovators </strong>— <a href="/service/mailto:partners@alix.vc">Click to Reach Out</a> 🚀</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*-HIOz8HFXB4krADuRZwfqg.png" /></figure><p><a href="https://www.linkedin.com/in/joeldudley"><strong><em>Joel Dudley</em></strong></a><em> is a partner at </em><a href="https://www.innovationendeavors.com/team/joel-dudley"><strong><em>Innovation Endeavors</em></strong></a><strong><em> </em></strong><em>and an experienced leader, medical professional, researcher, and entrepreneur. Joel previously served as the Chief Scientific Officer at </em><a href="https://www.tempus.com/"><em>Tempus</em></a><em>, a company focused on bringing the power of data and artificial intelligence to healthcare. Before joining Tempus, Joel was an Associate Professor of Genetics and Genomic Sciences and founding Director of the </em><a href="https://scholars.mssm.edu/en/organisations/institute-for-next-generation-healthcare"><em>Institute for Next Generation Healthcare</em></a><em> at the Icahn School of Medicine at Mount Sinai. He also served as Executive Vice President for Precision Health for the </em><a href="https://icahn.mssm.edu/"><em>Mount Sinai Health System</em></a><em>.‍</em></p><p><em>Prior to joining Innovation Endeavors, Joel co-founded Onegevity Health (acquired by </em><a href="https://www.thorne.com/onegevity-health-intelligence"><em>Thorne</em></a><em>), a company developing health intelligence platforms for preventative health, and </em><a href="https://numedii.com/"><em>NuMedii</em></a><em>, a company developing machine learning and A.I. approaches for drug discovery. Joel has published 200+ peer-reviewed research papers that have been referenced and featured in the New York Times, Wall Street Journal, Scientific American, MIT Technology Review, CNBC, and other popular media outlets. Joel earned a BS in Microbiology from Arizona State University and an MS and Ph.D. in Biomedical Informatics from the Stanford University School of Medicine.</em></p><h4>We sat down with Joel Dudley to ask his viewpoints on everything from top founder portfolio traits, seeking mentorship, to advice on preparing for fundraising…</h4><h4>1</h4><h4>What are the top 3 common traits of founders in your portfolio?</h4><blockquote>Smart with confident humility: There is typically a deep scientific insight underlying the companies we invest in, and those insights often come out of the founder’s academic lab, where they are among the top scientists in their scientific area of expertise. Spending as much time in academia as I have, it is unfortunately rare to find exceptional scientific ability and exceptional humility in the same individual. That can work just fine within the incentive structures of academia. However, when running a startup, you need to have the humility to know your weaknesses and be open to asking for input and feedback from board members and advisors. And you need to make critical early hires that have strengths that complement the founder’s weaknesses. We are lucky to have scientific founders in our portfolio that move forward with great confidence and intelligence because they have appropriate confidence in their scientific and technical abilities and appropriate humility in decision-making.</blockquote><blockquote>The ability to adopt an engineering mindset: Many of our companies are founded on scientific insights that have achieved proof-of-concept in an academic research setting. But in almost every case, the path to value will require developing strategies and technologies to scale up the initial proof-of-concept. Scaling beyond the proof-of-concept often requires adopting an engineering mindset where you think not only about systems designs of robotics, fluidics, data infrastructure, etc., but also the iterative process of design and optimization as well as frameworks for understanding engineering design trade-offs that arise as you engineer scientific platforms. You can hire the engineering mindset onto the team. However, the scientific founders must also understand and value the engineering mindset as a key aspect of scaling, value creation, and company success.</blockquote><blockquote>Short-term pragmatism grounded in a long-term vision: In a fast-moving startup, there is always going to be a tension between the long-term, transformative vision driving the company and the short-term pragmatics decisions that need to be made today to move the ball down the field towards the greater vision. When you consider something like a therapeutics company, you know you are signing up for a decade-plus endeavor to build something great and important. Pure scientists are often good at keeping their north star pointed toward an exciting and important long-term vision. However, they can sometimes have difficulty connecting all the key results and milestones between today and the future. That’s why it’s often important to pair scientific or academic founders with strong operators and executors, along with strong engineers who focus on building things and moving the ball down the field daily. And it is also important to hire leaders within the company who are good at navigating their teams along that fine line between short-term deliverables and long-term vision.</blockquote><h4>2</h4><h4>How does your investment criteria change in a recessionary environment?</h4><blockquote>“Our firm’s investment criteria are designed and principled to remain stable against the changing macroeconomic environment. For example, we perform thorough and technically or scientifically rigorous diligence on all opportunities regardless of how fast or slow deals appear to be moving. One thing we see now as a result of the changing investing environment is investors requiring therapeutics companies to have much more robust data packages establishing biological and clinical proofs-of-concept to trigger investments as early as Series A. This “raising of the bar” by investors is important to understand if you are building a technology-enabled therapeutics platform company. In recent, frothier years platform companies could raise large Series A and even Series B investments and use those funds to continue building their platform. We work with our therapeutics platform companies to ensure they strike a healthy balance between building the technology-enabled platform at their business’s core and developing a robust pipeline of assets supported by robust preclinical data packages and well-validated clinical hypotheses.”</blockquote><h4>3</h4><h4>How has your worldview evolved since you first started your VC career?</h4><blockquote>“That’s a really interesting question. My first thought is that I’m really blown away and humbled by many of the scientific funders who follow their conviction and go all-in on their startup idea. I’ve met so many passionate founders who are leaving tenured faculty positions, high-paying positions in biopharma, or other very comfortable and secure positions to go all-in on startups that have high degrees of technical or scientific risk. You tend to only hear about academic breakthroughs that make the headlines, and those are indeed important, but our society and industries benefit from so many intrepid founders who trade comfort for the challenge and risks required to turn science fiction into reality at scale.”</blockquote><h4>4</h4><h4>Outside of operating experience &amp; higher education, what is one seemingly random thing you look for in a founder’s background?</h4><blockquote>“I doubt I have any particularly novel insight regarding this question, but I appreciate it when founders are fond of science fiction. I’m probably dating myself here, but I’m a huge fan of Star Trek the Next Generation (STNG), and it’s amazing to see how many issues and concepts explored by STNG are relevant in A.I. and biotechnology today. It’s quite difficult to envision truly revolutionary science and technology when you iterate toward the future from today in incremental steps because it’s easy to become encumbered by the limitations of today’s science and technology. Science fiction offers the freedom to envision paths to future worlds of science and technology without those limitations.”</blockquote><h4>5</h4><h4>Outside of investing, what is one seemingly random activity that helps make you a better VC?</h4><blockquote>“Strangely enough, I’d have to say it’s weightlifting. I spent a lot of time getting into powerlifting as my main form of exercise, and nearly every injury I’ve suffered as a result of powerlifting came from “ego lifting.” “Ego lifting” refers to self-indulgent behaviors that cause you to become impatient and undisciplined due to chasing bigger and bigger weightlifting numbers. For example, you might try to lift a weight that is probably beyond your current strength level, but your ego convinces you to try it because you are so focused on hitting bigger numbers and getting that P.R. (personal record). Lifting heavy weights beyond your ability will almost always result in injury. I have several long-term injuries that are a result of ego lifting. Whenever I feel pain in my joints from a past ego lifting injury, it reminds me about the cost of giving into one’s ego. In my opinion, the proper course in powerlifting and investing is to keep your ego in check and stay the course and be patient enough to let good fundamental processes work and compound over time.”</blockquote><h4>6</h4><h4>What has been the most helpful piece of advice you received throughout your career as a venture capitalist?</h4><blockquote>“I’d say it’s one of the core values of our firm, which is to invest with high conviction. People sometimes ridicule the VC industry for having a herd mentality. While that characterization may be unfair and overplayed in most cases, I’ve experienced that there is some truth to that characterization in some cases. If all good investments were obvious, then you would not need to pay skilled partners to make hard investment decisions. I’m grateful that our firm hires investors with deep knowledge and experience and encourages them to follow their convictions in making investment decisions. I believe our firm’s track record speaks to the value of this high-conviction approach to investing.”</blockquote><h4>7</h4><h4>As an early stage investor, we often pick companies whose directions change. Can you talk about pivoting vs. staying the course?</h4><blockquote>“Given that I’m fairly early in my investing career, and the majority of my investments have fairly established go-to-market paths through the drug development cycle, I don’t think I have anything profound to say about pivoting with my investor hat on. I would highlight two things I think are important to keep in mind here. One, I’d refer back to my earliest comments about having humility and keeping your ego in check. Things go off the rails when you have stubborn founders who fail to heed well-intentioned and valuable advice on potential pivots from board members and other mentors in that founder’s life. The “sunk cost fallacy” is a dangerous trap for humans in general, so it can be hard to keep those cognitive biases at bay in any situation. The second thing I’d mention, and maybe this reveals my scientific background, is to have really clear questions (i.e., hypotheses) on potential pivots and clear sets of data and outcomes that would help you make more objective and informed decisions on pivoting. Unless you are a one-in-a-million founder, “winging it” on a pivot will likely end in disaster.”</blockquote><h4>8</h4><h4>As a founder building something new in the world, you are often in need of knowledge you don’t possess. How would you recommend founders go about seeking mentorship?</h4><blockquote>“This is a really important question. Some of the most impressive founders I’ve met, and this includes first-time founders, are the ones who had an innate inclination to seek out mentorship. Our firm is a big believer in supporting founders through feedback and mentorship, and we have some formal programs in place to encourage founders to establish these types of feedback-driven mentorship relationships. I’ve found that many successful entrepreneurs in the later stages of their careers almost always remember where they came from. They remember what it was like to be taking their first steps into entrepreneurship, and most of them are willing to give back to younger founders. So reaching out to late-career entrepreneurs in your field will yield a surprising willingness of experienced folks to offer some form of mentorship to younger folks. That being said, experienced entrepreneurs in the later stages of their careers will likely have more people asking for their help than they have time to give help. In my experience, mentors are willing to offer their time to individuals they perceive as receptive mentees. Meaning people who are humble and willing to listen to advice and people will apply mentorship insights towards some greater purpose other than enriching themselves. Experienced mentors are usually quite good at sniffing out transactional, self-serving folks from genuine ones. Many mentor-mentee relationships will develop organically between co-workers, etc. However, I would encourage young founders to reach out to potential mentors in their field with clear, succinct, and humble appeals for mentorship. You’d be surprised how many folks are eager to help total strangers achieve great and important things.”</blockquote><h4>9</h4><h4>How does your evaluation process change when it comes to backing first-time vs. repeat founders?</h4><blockquote>“I generally see the world through a Bayesian-type lens where I always try to estimate prior probabilities to help estimate conditional probabilities on various potential outcomes. So with repeat founders, you have access to a different set of prior probabilities that you don’t always have with first-time founders (though it is still often possible to derive useful priors in the latter case). That being said, the world is a complex dynamic system. So, while it is true that adages such as “past performance is the best predictor of future performance” and “failure is the greatest teacher” tend to be useful rules of thumb, I think you have to consider all possible variables when making an investment decision. And that includes checking your assumptions about the relevance of a given founder’s previous experience as a founder (or lack thereof) to a given investment thesis.”</blockquote><h4>10</h4><h4>How do you advise founders in your portfolio to prepare ahead of time for future fundraises?</h4><blockquote>“When planning for future fundraising, founders often hear me state one of my favorite adages as a skeptical optimist, which is, “Hope for the best, plan for the worst.” Again, I don’t think I have any particularly unique insights on this topic compared to more experienced investors. But I have noticed that many founders often underestimate the time they need to put into fundraising preparation and how long it will take them to raise the next round. Many founders also underestimate how important it is to build long-term relationships with investors and how important that can be for future fundraising. For example, your Series B lead investor may come from a relationship you build starting at the Seed stage. There is a big signal vs. noise problem when you look at the world from the investor side of the table, and I think that many founders forget about that because they are so laser-focused on executing their startup, as they should be. And firms have different sets of criteria and things they need to believe before making an investment, so you want to learn those different criteria and world views early on so you can have productive fundraising interactions. So you need to keep some time and focus on the longer arc of your fundraise, which includes thinking about rounds past just the next round. Circling back to my earlier comment about hoping for the best and planning for the worst, this means having a very clear and detailed plan for the various fundraising scenarios that could play out. For example, what happens “exactly” in the case of a smaller-than-expected raise or a failed raise altogether? Can you raise an extension? How exactly will you cut burn, and what milestones precisely will you hit to get another swing of the bat at raising the next round? What about the high-class problem of having an oversubscribed round? Would you take more money, and if so, how would you put that money to work exactly? And what about all the possible scenarios between those two extremes? We like our companies to have deeply prepared minds when they head into fundraising so that they can be very intentional in their fundraise, provide crisp and detailed answers to investor questions, and also so they don’t get derailed when fundraising doesn’t go as they envisioned. A lot of this seems obvious, but it takes deliberate and conscious effort to develop a prepared mind ahead of fundraising rather than seeing it as a necessary nuisance that is distracting you from purely grinding on the core business.”</blockquote><p>📣 <strong>If you enjoyed this post please clap 👏 &amp; comment </strong>💬 <strong>to let us know</strong></p><p>❤️ Thanks <a href="https://medium.com/u/d4a12fd97637?source=post_page-----1b4f1f3e5213-----------------------------------"><strong>Andrew Yashar</strong></a> for your help in putting this together :)</p><h3>Join BIOS Community 🎉</h3><p>Become a member, continue the conversation, connect with like-minded Life Science innovators, access exclusive resources, &amp; invite-only events…</p><p><strong>Apply to Join — </strong><a href="https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform"><strong>Membership Application</strong></a></p><h3>For More Interesting Content 💭</h3><p>🧬 <strong>Podcast</strong> — <a href="https://open.spotify.com/show/2HmcPq9k8fYpn60F3hw6Ra?si=Qk9UeVGUSQajclaTYzN2uQ">Stream Full Episodes</a></p><p>🧪 <strong>YouTube </strong>— <a href="https://www.youtube.com/channel/UCWadRaYPrE1kE4t9LuCd28w">Watch Videos</a></p><p>🩺<strong> Twitter </strong>— <a href="https://twitter.com/bios_community">Explore Feed</a></p><p>🦠 <strong>LinkedIn</strong> — <a href="https://www.linkedin.com/company/bios-community">Read Posts</a></p><p><strong>Subscribe to BIOS Newsletter for special content: </strong><a href="https://www.bios.community/content"><strong>Click Here</strong></a><strong> 🔥</strong></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2a8973a524fe" width="1" height="1" alt=""><hr><p><a href="https://medium.com/bios-community/10-questions-w-joel-dudley-partner-innovation-endeavors-2a8973a524fe">10 Questions w/ Joel Dudley — Partner @ Innovation Endeavors</a> was originally published in <a href="https://medium.com/bios-community">BIOS Community</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Founder Spotlight #51: Nikole Kimes @ Siolta Therapeutics]]></title>
            <link>https://medium.com/bios-community/founder-spotlight-51-nikole-kimes-siolta-therapeutics-be4721cdaf7b?source=rss-183f327fce8c------2</link>
            <guid isPermaLink="false">https://medium.com/p/be4721cdaf7b</guid>
            <category><![CDATA[biotech]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[founders-spotlight]]></category>
            <category><![CDATA[science]]></category>
            <category><![CDATA[venture-capital]]></category>
            <dc:creator><![CDATA[BIOS]]></dc:creator>
            <pubDate>Thu, 10 Aug 2023 19:29:08 GMT</pubDate>
            <atom:updated>2023-11-10T17:32:45.720Z</atom:updated>
            <content:encoded><![CDATA[<p><a href="https://www.bios.community/"><strong><em>BIOS</em></strong></a><strong><em>: </em></strong><em>Nucleus of Life Science Innovation 🚀</em></p><h4>JOBS</h4><ul><li><strong><em>BIOS Talent: </em></strong><a href="https://medium.com/bios-community/bios-talent-worlds-first-techbio-job-board-weekly-newsletter-7d747d78dfaa"><em>Find Jobs @ Breakout TechBio Companies </em></a><em>— </em><a href="https://jobs.bios.community/companies"><strong><em>Search Jobs</em></strong></a><em> 🚀</em></li><li><strong><em>Post Jobs: </em></strong><em>Add Your Startup to BIOS Talent — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLScR_bLlCQ7Ie6bJ_HZ_dJ_LmuV3TsDEi-aNDC8N9GPz6psk1Q/viewform"><strong><em>Post Now</em></strong></a><strong><em> </em></strong><em>🎉</em></li><li><strong><em>Students:</em></strong><em> </em><a href="https://www.alix.vc/students"><em>Join Alix Ventures Fellowship</em></a><em> — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSckliaB67e-W2o9cmSbRNPLKrBBmtAx_S6CiFufc6QwHSCWSg/viewform"><strong><em>Join Now</em></strong></a><em> 🧬</em></li><li><strong><em>BIOS Contributor:</em></strong><em> </em><a href="https://medium.com/bios-community/write-for-bios-guest-contributor-aff9fbe6e1e"><em>Share Your Thought Leadership</em></a><em> — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSdGPtCdigoAu0ePKvsgcq08qPwRFWkKrHOjIQe7nCP5II_Xeg/viewform"><strong><em>Join Now</em></strong></a><em>🔬</em></li></ul><h4>CONTENT &amp; COMMUNITY</h4><ul><li><strong><em>BIOS Daily:</em></strong><em> Join 25K+ Subscribers Following TechBio — </em><a href="https://www.bios.community/content"><strong><em>Sign Up</em></strong></a><em> 🔥</em></li><li><strong><em>BIOS Insider: </em></strong><em>Premium TechBio Thought Leadership — </em><a href="https://bioscommunity.substack.com/"><strong><em>Sign Up</em></strong></a><strong><em> </em></strong><em>✨</em></li><li><strong><em>BIOS Commons: </em></strong><a href="https://medium.com/bios-community/introducing-bios-fostering-early-stage-healthcare-life-sciences-innovation-78c11dd57fff"><em>World’s Largest #TechBio Community</em></a><em> — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform"><strong><em>Join Now</em></strong></a><strong><em> </em></strong><em>🎉</em></li></ul><h4>INVEST</h4><ul><li><strong><em>BIOS Angels:</em></strong><em> </em><a href="https://medium.com/bios-community/introducing-bios-angels-worlds-1st-techbio-angel-syndicate-5faec24d8439"><em>1st TechBio Angel Investing Syndicate </em></a><em>— </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSe_0k-Ehi2uzTa_geqDm_B9kuRVWNyrvWSU7ch_5hqEKMoahg/viewform"><strong><em>Join Now</em></strong></a><strong><em> </em></strong><em>🌟</em></li><li><strong><em>Alix Limited: </em></strong><em>Invest in Breakout TechBio Startups — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSfqKG3fZOcXTtZTwKEk3wOvN0CyIIUBZkn-FFf5JhRHE1zW0Q/viewform"><strong><em>Learn More</em></strong></a><strong><em> </em></strong><em>🧠</em></li></ul><h4>By:</h4><p><a href="https://www.alix.vc/"><strong><em>Alix Ventures</em></strong></a><strong><em>: </em></strong><em>Supporting Early Stage Life Science Startups Engineering Biology to Drive Radical Advances in Human Health</em></p><p><strong><em>Calling All Innovators </em></strong><em>— </em><a href="/service/mailto:partners@alix.vc"><em>Click to Reach Out</em></a><em> 🚀</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*gneb6gafN9VFnOBdgGoMKw.png" /></figure><p><a href="https://www.sioltatherapeutics.com/"><strong><em>Siolta Therapeutics</em></strong></a><strong><em> </em></strong><em>is a clinical-stage biopharmaceutical company developing targeted microbiome-based therapeutics to prevent and treat diseases of high unmet medical need. Its lead program, STMC-103H is currently in phase 2 development to prevent atopic diseases in at-risk newborns. Siolta has successfully scaled up a multi-strain LBP drug product STMC-103H (&gt;100K doses), completed a First-In-Human descending-age clinical trial (STMC-103H-101), and was recently awarded a $2.7M NIH grant to further advance its proprietary mixed-strain LBP manufacturing methods. By leveraging its Precision Symbiotics Platform™ the company is expanding its product pipeline into additional pediatric and women’s health indications.</em></p><p><a href="https://www.linkedin.com/in/nikole-kimes-4b357786/"><strong><em>Nikole Kimes</em></strong></a><strong><em> </em></strong><em>is CEO &amp; Co-Founder @ Siolta Therapeutics. Driving Siolta’s early-stage development, Nikole heads a talented team of scientists, blending microbiology, immunology, and bioinformatics expertise to leverage microbiome data for the improvement of patient stratification and development of precision microbial therapeutics. Nikole has over a decade of experience in microbial ecology and host/microbe interactions, supported by the National Science Foundation (NSF), the European Commission FP7, and the University of California San Francisco (UCSF). As an inventor of Siolta’s technology, her research in Susan Lynch’s lab @ UCSF provided the foundation for the company’s translational research program. Nikole is also the Chairman of the Microbiome Therapeutics Innovation Group (MTIG), an independent coalition of companies leading the research and development of FDA-approved microbiome therapeutics to address unmet medical needs, improve clinical outcomes, and reduce health care costs.</em></p><h3>Personal Spark</h3><h4>What prompted you to pursue a career in Life Sciences? Was there a specific moment in time or influence you can remember? What drives you to work in this space?</h4><p>I have always had two loves from an academic and career perspective: human health and environmental science. These concepts were often presented as competing interests despite my intuitive sense suggesting that they are intrinsically and inextricably linked. Thus, my early academic career was a bit meandering as I attempted to find ways to combine both passions in a single career objective.</p><p>Early in my career, I obtained a BS in science and a MA in holistic health, followed by a stint in the Peace Corp teaching human health, environmental education, and basic business principles, and after which I returned to human health doing neurobiology research. Although each of these events were vital to my development, I had not yet successfully integrated my interests in a meaningful manner.</p><p>As a result, I kept searching for something I could not yet name or fully describe. I eventually found myself in a unique opportunity to participate in a PhD program at the Medical University of South Carolina (MUSC) that combined environmentally focused molecular and cellular biology with translational human health. Although the genesis for this program was more of a small molecule drug discovery approach, my exposure to systems biology was life altering and afforded me the “ah ha” moment that I had been seeking.</p><h4>Can you tell us a bit about your background &amp; career thus far? What were you doing before you started leading a startup?</h4><p>My doctoral work focused on characterizing environmental microbiomes (e.g., the coral microbiome) both taxonomically and functionally. My particular focus was on how these amazing microbial systems were influenced by changing environmental parameters and consequently impacted the health of the entire ecosystem. During this time, I learned to appreciate not only the intricacies of specific molecular interactions but also the complexity of interdependent networks driving a given ecosystem’s functionality.</p><p>This grand awakening in my own education occurred in parallel with the broader microbiome revolution that has changed our understanding of all ecosystems, including the human holobiont. A term that references the co-evolution of human beings with their complex microbial counterpart, the human microbiome. It was always my belief that if we could unlock the connection between our environment and our health, we would be able to address health conditions that had to date remained significant unmet clinical needs due to their complexity and recalcitrant nature (e.g., chronic inflammatory diseases and multi-factorial infections). At this point in my education, I had the tools to elucidate more specifically how the human microbiome connected our environmental exposures to our long-term health. This revelation and knowledge provided a much clearer vision of my future from an academic and career perspective.</p><p>Importantly, my family and I chose to return to San Francisco where I sought to find an innovative scientist as a mentor in the human microbiome space. This was a critical step in which I had the privilege of working with an amazing scientist, Dr. Susan Lynch at UCSF. She had incorporated an ecological perspective into her understanding of the human microbiome and more specifically its impact on systemic health through immunomodulation in early life development. This approach and years of scientific research coming out of Sue’s lab was eventually the foundation on which we have built Siolta Therapeutics.</p><h3>Genesis</h3><h4>Tell us about the founding of your company — how did everything come together?</h4><p>The founding of Siolta Therapeutics at its very foundation is a scientific story. Dr. Lynch is a pioneer in the human microbiome field, and her work has moved far beyond the early characterization studies. In fact, her work has provided greater understanding of the gut microbiome’s systemic modulation of immune development and overall health. As a result of her work at UCSF, Sue worked with influential people, such as Marc Benioff, and eventually interacted with the different players in biotech, including venture capitalists such as Samir Kaul. As a result in 2016, there was a fortuitous alignment of factors. First and most importantly, the science proved to be compelling in a more mature manner than previously. Second, the interest in backing an innovative approach that would truly transform our approach to healthcare existed. Finally, although I had never previously considered becoming an entrepreneur, I was open to the unique opportunity at hand.</p><p>What felt random in the moment proved to make perfect sense in reflection. Much like Systems biology is not a linear process; founding a successful company requires an almost mystical confluence of events in a complex, yet systematic way that is not always obvious initially.</p><h4>How did you get your training, if any, to be able to build your company?</h4><p>The early days consisted of a lot of on the job learning. The amazingly supportive early biotech support systems available in the Bay area, MBC BioLabs and California Life Sciences for example, were also essential to our initial success. I learned the vast majority of what I needed to know through a welcoming community that openly and willingly shared their experiences and resources. I was willing to ask questions about all the things I never even knew I needed to know to develop therapeutics, everything from business licenses to intellectual property to accounting practices. The skills for building a team were a bit more intuitive, although they needed to be fostered through mentoring and guidance. Interestingly for me, I found all the new aspects of daily life to be just as compelling as the science, and eventually it became clear that I was actually the perfect person to lead this company on a such a unique journey.</p><h3>Company Overview</h3><h4>What problem is your company solving?</h4><p>Traditional drug development often utilizes screened molecules to target specific pathways in the body that help alleviate the symptoms of disease. Although effective in many ways, this approach does not alleviate the underlying cause of disease and often is associated with unwanted side-effects. In contrast, our microbiome-based therapeutics are designed to work with the body’s natural systems to stop diseases before they start. We know that the human microbiome plays essential roles across a broad spectrum of critical functionalities in healthy individuals, including proper metabolism, immune modulation, inflammatory signaling, and even neurophysiology. This provides a natural reservoir of synergistic therapeutic agents that can work together to address the underpinnings of complex and multifactorial diseases, and we founded Siolta to develop targeted microbiome-based therapeutics that have the potential to be more efficacious with less side-effects.</p><h4>How did you become motivated to tackle this particular problem?</h4><p>Through our work at USCF, we recognized that the gut microbiome plays a critical role in regulating the immune system and that modulating it could potentially provide a novel approach to treating inflammatory-related diseases. Our team at Siolta Therapeutics have been working on developing therapeutics that can restore the balance of the human microbiome in infants at risk of developing atopic diseases (i.e., atopic dermatitis, food allergy, and allergic asthma) as well as other indications.</p><h4>Quite simply, what does your company do?</h4><p>Most simply stated, we are harnessing the human microbiome to develop a new class of drugs that will address the underlying causes of disease. To do this, we are integrating sophisticated bioinformatics with complex biology to develop targeted therapeutics and diagnostics across a number of indications.</p><h4>Now in more depth, what are the specifics of what your company does?</h4><p>Siolta Therapeutics is a clinical-stage biotechnology company that develops targeted microbiome-based therapeutics to prevent and treat diseases of high unmet medical need. Our lead program, STMC-103H is currently in phase 2 development to prevent atopic diseases in at-risk newborns.</p><p>Our targeted consortia Live Biotherapeutic Products (LBPs) are defined, multi-strain, combinations of live bacteria of high therapeutic value, isolated from the healthy human microbiome, and manufactured under strict pharmaceutical grade GMP standards.</p><p>Siolta Therapeutics is a biotechnology company that develops microbiome-based therapies to treat and prevent inflammatory diseases and recurrent infections. The company’s initial focus is on the role of the gut microbiome in immune system development and function. Siolta’s lead therapeutic candidate is a live biotherapeutic product called STMC-103H, which is designed to modulate the gut microbiome to prevent or treat a range of inflammatory diseases, including allergic asthma and eczema. Siolta is also developing a pipeline of microbiome-based therapies for unmet needs in women’s health and rare pediatric disease.</p><h4>Why does your solution matter for the world when you get it right?</h4><p>Imagine holding your new born baby and knowing that they are at-risk for developing a life-long chronic disease. Now imagine being provided a relatively low-cost solution that you provide in the first months of life that would alleviate that outcome. Siolta’s approach is to target multiple mechanisms of action simultaneously in order to solve for the underlying “root” cause of disease, rather than simply addressing individual symptoms. This approach has the potential to provide more comprehensive and long-lasting treatment outcomes for patients. This approach of addressing disease before it causes permanent damage is a fundamentally different way of thinking about healthcare. Not only would it transform health outcomes, it would also dramatically reduce the cost burden of such diseases.</p><h3>Accomplishments</h3><h4>What are some of the notable milestones your company has achieved thus far?</h4><p>Deciding to start a company, I imagine is never an easy task. We are focused on a solution that involves emerging technology; we are integrating a transformative approach focused on prevention; and we believe that we will be most impactful if we start with our children. Although traditional drug development norms would readily argue against our approach, the science is telling us something different. At Siolta we are compelled by the science to follow a different path, and we are proud of the team we’ve built both internally and externally to support such a unique endeavor. Although we have had to build each stepping stone along the way, we have successfully navigated a path from academic ideation into clinical trials to test this potentially groundbreaking approach in an amazingly efficient manner having added significant value and de-risked our future efforts substantially.</p><p>Siolta has successfully scaled up a multi-strain LBP drug product STMC-103H (&gt;100K doses), completed a First-In-Human descending-age clinical trial (STMC-103H-101), and was recently awarded a $2.7M NIH grant to further advance its proprietary mixed-strain LBP manufacturing methods. By leveraging its Precision Symbiotics Platform™ the company is expanding its product pipeline into additional pediatric and women’s health indications.</p><h4>What are some of the biggest hurdles ahead? How do these create points of value inflection?</h4><p>We are currently enrolling in our Phase 2 adored study for the prevention of allergic diseases in newborns. Making sure that we continue to attract talent to our team.</p><h3>Pay It Forward</h3><h4>Throughout the journey, what have been some of your biggest takeaways thus far? What advice/words of wisdom would you share from your story for other founders?</h4><p>Systems, whether they are ecosystems, biological systems or even human systems, are always complex, multifactorial, and powerful. From this perspective rarely is anything a simple linear equation. One of the greatest lessons I’ve absorbed along this journey has been to accept a systems perspective for my own life trajectory. Often, we like to think of successful leaders as being visionaries who knew from day one what the solution needed to be. When in reality there is a complex web of experiences, knowledge and serendipity that occurs over time driving the greatest outcomes. As an entrepreneur, do not be fooled into thinking there is “a right path” because there are always alternatives and it’s more important to find the path that is uniquely suited for you. As long as you have an idea, determination, and resources, it can be done in many different ways.</p><h4>What are some of the must-haves for an early stage Life Sciences startup in your eyes? (Key critical components like team, academic papers, industry know-how, etc.)</h4><p>The right team, mission and vision. Also make sure you have strong IP to operate in your space.</p><h4>What are some of the traits that make a good founder? What type of risk profile/archetype does someone need to have to be a founder in your opinion?</h4><p>Grit and strong persistence. Determination to keep going.</p><h4>For folks coming out of academia, what advice would you share?</h4><p>Do enough market research on the industry you’re planning to go into. Talk to as many people as possible about the problem you’re trying to solve.</p><h4>Not everyone knows everything. Often founders have to learn either the science or the business side better. What advice would you give for someone picking up a new skill set such as this?</h4><p>Find great advisors and mentors. There are also a number of great accelerator and incubator groups these days like Nucleate or Pillar VC.</p><h4>Can you demystify the process of what it takes to raise VC funding? What were the highlights &amp; lowlights? Any advice or words of wisdom for future founders?</h4><p>Remember to stay grounded, and make time for yourself during the fundraising process. It can get tough at times, so make sure you have a strong support network and system. You have to find the right investors who will believe and support you on a long-term basis, and if that fit isn’t right — move on. Bringing on a VC or investor to your Board who is not aligned with your vision, will significantly hinder company growth. Make sure you’re focusing on the right fit, and not just the term sheet.</p><h4>What advice for managing and hiring a great team can you share?</h4><p>Hire A-level team members. Hire the best talent, to create the best work. Provide an internal culture for mentorship and training for onboarding.</p><p>📣 <strong>If you enjoyed this post please clap 👏 &amp; comment </strong>💬 <strong>to let us know</strong></p><p><em>Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement or recommendation by Alix Ventures, BIOS Community, or its affiliates. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by Alix Ventures employees are those of the employees and do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, and content sponsors.</em></p><h3>Join BIOS Community 🎉</h3><p>Become a member, continue the conversation, connect with like-minded Life Science innovators, access exclusive resources, &amp; invite-only events…</p><p><strong>Apply to Join — </strong><a href="https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform"><strong>Membership Application</strong></a></p><h3>For More Interesting Content 💭</h3><p>🧬 <strong>Podcast</strong> — <a href="https://open.spotify.com/show/2HmcPq9k8fYpn60F3hw6Ra?si=Qk9UeVGUSQajclaTYzN2uQ">Stream Full Episodes</a></p><p>🧪 <strong>YouTube </strong>— <a href="https://www.youtube.com/channel/UCWadRaYPrE1kE4t9LuCd28w">Watch Videos</a></p><p>🩺<strong> Twitter </strong>— <a href="https://twitter.com/bios_community">Explore Feed</a></p><p>🦠 <strong>LinkedIn</strong> — <a href="https://www.linkedin.com/company/bios-community">Read Posts</a></p><h4>Subscribe to BIOS Newsletter for special content: <a href="https://www.bios.community/content">Click Here</a> 🔥</h4><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=be4721cdaf7b" width="1" height="1" alt=""><hr><p><a href="https://medium.com/bios-community/founder-spotlight-51-nikole-kimes-siolta-therapeutics-be4721cdaf7b">Founder Spotlight #51: Nikole Kimes @ Siolta Therapeutics</a> was originally published in <a href="https://medium.com/bios-community">BIOS Community</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[10 Questions w/ Gordana Vunjak-Novaković — University Professor @ Columbia]]></title>
            <link>https://medium.com/bios-community/10-questions-w-gordana-vunjak-novakovi%C4%87-university-professor-columbia-b44d7e7b08fb?source=rss-183f327fce8c------2</link>
            <guid isPermaLink="false">https://medium.com/p/b44d7e7b08fb</guid>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[academia]]></category>
            <category><![CDATA[research]]></category>
            <category><![CDATA[science]]></category>
            <category><![CDATA[startup]]></category>
            <dc:creator><![CDATA[BIOS]]></dc:creator>
            <pubDate>Thu, 13 Jul 2023 18:00:40 GMT</pubDate>
            <atom:updated>2023-07-17T18:11:13.673Z</atom:updated>
            <content:encoded><![CDATA[<h3>10 Questions w/ Gordana Vunjak-Novaković — University Professor @ Columbia</h3><p><a href="https://www.bios.community/"><strong>BIOS</strong></a><strong>: </strong>Nucleus of Life Science Innovation 🚀</p><p><strong>JOBS</strong></p><ul><li><strong>BIOS Talent: </strong>Find Jobs @ Breakout TechBio Startups — <a href="https://jobs.bios.community/companies"><strong><em>Search Jobs</em></strong></a> 🚀</li><li><strong>Post Jobs: </strong>Add Your Startup to BIOS Talent — <a href="https://docs.google.com/forms/d/e/1FAIpQLScR_bLlCQ7Ie6bJ_HZ_dJ_LmuV3TsDEi-aNDC8N9GPz6psk1Q/viewform"><strong><em>Post Now</em></strong></a><strong><em> </em></strong>🎉</li><li><strong>Students:</strong> <a href="https://www.alix.vc/students">Join Alix Ventures Fellowship</a> — <a href="https://docs.google.com/forms/d/e/1FAIpQLSckliaB67e-W2o9cmSbRNPLKrBBmtAx_S6CiFufc6QwHSCWSg/viewform"><strong>J<em>oin Now</em></strong></a><em> </em>🧬</li><li><strong>BIOS Contributor:</strong><em> </em><a href="https://medium.com/bios-community/write-for-bios-guest-contributor-aff9fbe6e1e">Share Your Thought Leadership</a> — <a href="https://docs.google.com/forms/d/e/1FAIpQLSdGPtCdigoAu0ePKvsgcq08qPwRFWkKrHOjIQe7nCP5II_Xeg/viewform"><strong><em>Join Now</em></strong></a></li></ul><p><strong>CONTENT &amp; COMMUNITY</strong></p><ul><li><strong>BIOS Daily:</strong> Join <em>25K+</em> Subscribers Following TechBio — <a href="https://www.bios.community/content"><strong><em>Sign Up</em></strong></a><em> </em>🔥</li><li><strong>BIOS Insider: </strong>Premium TechBio Thought Leadership — <a href="https://bioscommunity.substack.com/"><strong><em>Sign Up</em></strong></a><strong> </strong>✨</li><li><strong>BIOS Commons: </strong><a href="https://medium.com/bios-community/introducing-bios-fostering-early-stage-healthcare-life-sciences-innovation-78c11dd57fff">World’s Largest <em>#TechBio </em>Community</a> — <a href="https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform"><strong><em>Join Now</em></strong></a><strong><em> </em></strong>🎉</li></ul><p><strong>INVEST</strong></p><ul><li><strong>BIOS Angels:</strong> <a href="https://medium.com/bios-community/introducing-bios-angels-worlds-1st-techbio-angel-syndicate-5faec24d8439">1st TechBio Angel Investing Syndicate </a>— <a href="https://docs.google.com/forms/d/e/1FAIpQLSe_0k-Ehi2uzTa_geqDm_B9kuRVWNyrvWSU7ch_5hqEKMoahg/viewform"><strong><em>Join Now</em></strong></a><strong><em> </em></strong>🌟</li><li><strong>Alix Limited: </strong>Invest in Breakout TechBio Startups — <a href="https://docs.google.com/forms/d/e/1FAIpQLSfqKG3fZOcXTtZTwKEk3wOvN0CyIIUBZkn-FFf5JhRHE1zW0Q/viewform"><strong><em>Learn More</em></strong></a><strong><em> </em></strong>🧠</li></ul><p><strong>By:</strong></p><p><a href="https://www.alix.vc/"><strong>Alix Ventures</strong></a><strong>: </strong>Supporting Early Stage Life Science Startups Engineering Biology to Drive Radical Advances in Human Health</p><p><strong>Calling All Innovators </strong>— <a href="/service/mailto:partners@alix.vc">Click to Reach Out</a> 🚀</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*azv2W3omQ2gp9UkG-faztw.png" /></figure><p><a href="https://www.bme.columbia.edu/gordana-vunjak-novakovic"><strong><em>Gordana Vunjak-Novaković</em></strong></a><em> is a University Professor @ Columbia University (First engineer in the history of Columbia to receive this highest distinction), Mikati Foundation Professor of Biomedical Engineering &amp; Medical Sciences, Professor of Dental Medicine, Directs the Tissue Engineering Resource Center, and Columbia’s Center for Dental &amp; Craniofacial Research. Vunjak-Novakovic’s research interest is focused on tissue engineering, where her lab has pioneered the development of innovative technologies for engineering functional human tissues and organs.</em></p><p><em>Vunjak-Novaković’s diverse team of engineers, clinicians, and scientists is developing innovative tissue engineering technologies for improving human health. Her Laboratory for Stem Cells and Tissue Engineering is interested in whole organ engineering for regenerative medicine, tissue models for biological research, and “organs-on-a-chip” platforms for disease modeling and drug development. To this end, her team directs the human cell differentiation and assembly into functional tissues using a “cell-instructive” approach based on tissue-specific scaffolds (providing templates for tissue formation) and advanced bioreactors (providing environmental control, molecular and physical signaling).</em></p><p><em>Vunjak-Novaković’s laboratory is a home to the national Tissue Engineering Resource Center that is funded by NIH to foster tissue engineering for medical impact, and is actively collaborating with colleagues at both campuses of Columbia University, nationwide, and around the world. Vunjak-Novakovic is also part of CELL-MET, a multi-institutional National Science Foundation Engineering Research Center in Cellular Metamaterials that is based at Boston university. CELL-MET aims to grow functional and clinically relevant heart tissue while simultaneously developing a talented and diverse workforce to tackle future challenges in tissue engineering.</em></p><p><em>To translate their science into new therapeutic modalities, her lab has launched four biotech companies: </em><a href="http://epibone.com/"><strong><em>epiBone</em></strong></a><em>, </em><a href="http://tarabiosystems.com/"><strong><em>Tara</em></strong></a><em> (Acquired by Valo Health), </em><a href="http://xylyxbio.com/"><strong><em>Xylyx Biosolutions</em></strong></a><em>, &amp; </em><a href="http://immplacatehealth.com/"><strong><em>Immplacate</em></strong></a><em>.</em></p><h4>We sat down with Gordana Vunjak-Novaković to ask her viewpoints on everything from entrepreneurial lab culture, what she looks for in new research topics, to advice on building companies…</h4><h4>1</h4><h4>What advice would you give to founders working with University Tech Transfer looking to spinout out a company?</h4><blockquote>“Your University’s Tech Transfer Office can be incredibly helpful at every single step of the process. They are professionals working for you. They know how to coordinate the filing of IP with publications, and provide you and your lab with the training workshops, market/regulatory support and valuable networks of investors and professionals. The founders should understand how exactly this office works and develop a good working relationship. I always seek and follow their advice.”</blockquote><h4>2</h4><h4>Can you describe your process for vetting new ideas to pursue in your lab?</h4><blockquote>“Our lab is highly translational, meaning that we always think about how we can benefit medicine and society. This is true both for our scientific studies and entrepreneurial efforts. My approach is to get the best people I can and to help them pursue their own passion for science. Such creative freedom results in many ideas that we are vetting by evaluating their potential impact, feasibility to meet one of the real needs, and the competitive edge of our team. In doing this, we try to get as much advice as possible from experts and prospective users.”</blockquote><h4>3</h4><h4>How do you establish an effective entrepreneurial lab culture?</h4><blockquote>“Our role is to provide a collaborative lab environment that encourages creativity and supports trainees in pursuing their own ideas. This way, our trainees have the intellectual ownership over their research, with long lasting implications. As some of the ideas evolve into candidates for translation, my trainees follow their technologies into the startup companies we founded. Going full circle from being inventors on patents to co-authoring papers and commercializing the resulting technology has made a world of difference in this journey and its outcomes.</blockquote><blockquote>I think we will all agree that failing is an integral part of research and translation, and that failing can provide more valuable insights than the experiments that progressed as planned. It is important to make this a fundamental principle for research in our labs. Not failing may also suggest that we are not innovating enough.</blockquote><blockquote>It is equally important to encourage finding inspiration in clinical and societal needs. The classical “bench to bedside” paradigm is now evolving to start from bedside (to identify the problem), move to bench (to find a solution) and circle back to bedside (for implementation).</blockquote><blockquote>This brings us to the third key component of our lab culture: collaboration. Collaborators, and especially the experts outside our zone of comfort, are invaluable, as they help us formulate the right questions, find new approaches to long-standing problems, and be mindful of implementation constraints and strategies. Collaborations also lead to working at the interfaces of disciplines, where we find some of the most exciting science.”</blockquote><h4>4</h4><h4>What advice would you give to professors trying to entrepreneurialize their labs?</h4><blockquote>“Some trainees are born scientists, some are entrepreneurs and some are both. And some do not know right away what their interests and strengths are. Our job is to help the later ones find their perfect match, and to enable and support everyone in pursuing the path they are passionate about. Clearly, it is most difficult for a student, postdoc or clinical fellow to ask the right question and understand what are their greatest strengths. This is where our help is most critically needed, and in an individualized fashion.</blockquote><blockquote>There are also many general skills for which we need to provide guidance and opportunities to learn and to practice by doing. Many of my trainees took entrepreneurship-related classes (some of them even completing the MBA), and participated in workshops, bootcamps and other training modalities provided by Columbia, our Technology Ventures Office and NSF funded programs. Summer internships in startup companies and participation in events organized by the local entrepreneurial community are also very helpful.</blockquote><blockquote>While we need to prioritize science and training, we also need to play a supporting role in commercialization of technologies developed in the lab. It is critical to separate the two, keep the lab up to date with all efforts, and be mindful of any conflicts of interest that need to be resolved.”</blockquote><h4>5</h4><h4>Outside of academia, what is one seemingly random activity that helps make you a better researcher?</h4><blockquote>“Being in academia is the best “job” in the world, it is a lifestyle encompassing a lot of “random activities”. Reading, film, travel and dinners with friends are part of it, with family being most central to everything. I believe that my passion for science makes me a better person, and that my family makes me a better scientist. They are inseparable in the way they support each other.”</blockquote><h4>6</h4><h4>How do you identify the point at which a scientific discovery is ripe for commercialization?</h4><blockquote>“There is always a “killer experiment” that rigorously tests the technology. If this experiment is successful and there is clearly an unmet need we can address, it makes sense to proceed. And if you will fail — fail early, before investing too much time and resources,”</blockquote><h4>7</h4><h4>What advice can you give to academics raising their first round of venture funding?</h4><blockquote>“It is really important that your investors bring to you more than funding. They should be your partners, share the same ideas and goals, and feel comfortable and passionate about the journey that you are about to undertake. It may take time to find the right partner, but this decision may largely determine if you will succeed or fail.”</blockquote><h4>8</h4><h4>What advice would you give to business professionals looking to get in contact/help commercialize startups spinning out of academia?</h4><blockquote>“It is common to find a great team behind a great technology. Looking into people and their track record in translational science is at least as important as evaluating the technology.”</blockquote><h4>9</h4><h4>What advice would you give to professors in balancing founding a company and continuing to pursue academic research?</h4><blockquote>“I think we should act as enablers of our trainees in their scientific and entrepreneurial interests, while keeping focus on our science. Running a company is a full-time job, as is running an academic lab. The best we can do is to trust and support our trainees-entrepreneurs. This means being available to advise on science and technology and to help with connections to experts and investors, while staying out of the way.”</blockquote><h4>10</h4><h4>What has been the most helpful piece of advice you received throughout your career as an academic entrepreneur?</h4><blockquote>“Find inspiration for your science in unmet clinical and societal needs. Team up with great people. Get expert advice.”</blockquote><p>📣 <strong>If you enjoyed this post please clap 👏 &amp; comment </strong>💬 <strong>to let us know</strong></p><p>❤️ Thanks <a href="https://medium.com/u/d4a12fd97637?source=post_page-----1b4f1f3e5213-----------------------------------"><strong>Andrew Yashar</strong></a> for your help in putting this together :)</p><h3>Join BIOS Community 🎉</h3><p>Become a member, continue the conversation, connect with like-minded Life Science innovators, access exclusive resources, &amp; invite-only events…</p><p><strong>Apply to Join — </strong><a href="https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform"><strong>Membership Application</strong></a></p><h3>For More Interesting Content 💭</h3><p>🧬 <strong>Podcast</strong> — <a href="https://open.spotify.com/show/2HmcPq9k8fYpn60F3hw6Ra?si=Qk9UeVGUSQajclaTYzN2uQ">Stream Full Episodes</a></p><p>🧪 <strong>YouTube </strong>— <a href="https://www.youtube.com/channel/UCWadRaYPrE1kE4t9LuCd28w">Watch Videos</a></p><p>🩺<strong> Twitter </strong>— <a href="https://twitter.com/bios_community">Explore Feed</a></p><p>🦠 <strong>LinkedIn</strong> — <a href="https://www.linkedin.com/company/bios-community">Read Posts</a></p><p><strong>Subscribe to BIOS Newsletter for special content: </strong><a href="https://www.bios.community/content"><strong>Click Here</strong></a><strong> 🔥</strong></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=b44d7e7b08fb" width="1" height="1" alt=""><hr><p><a href="https://medium.com/bios-community/10-questions-w-gordana-vunjak-novakovi%C4%87-university-professor-columbia-b44d7e7b08fb">10 Questions w/ Gordana Vunjak-Novaković — University Professor @ Columbia</a> was originally published in <a href="https://medium.com/bios-community">BIOS Community</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Recap — Season 2: 10/10 VC Series]]></title>
            <link>https://medium.com/bios-community/recap-season-2-10-10-vc-series-388afdf4ac72?source=rss-183f327fce8c------2</link>
            <guid isPermaLink="false">https://medium.com/p/388afdf4ac72</guid>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[1010-series]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[entrepreneurship]]></category>
            <category><![CDATA[founders]]></category>
            <dc:creator><![CDATA[BIOS]]></dc:creator>
            <pubDate>Thu, 04 May 2023 04:41:43 GMT</pubDate>
            <atom:updated>2023-05-04T04:41:43.129Z</atom:updated>
            <content:encoded><![CDATA[<h3>Recap — Season 2: 10/10 VC Series</h3><p><a href="https://www.bios.community/"><strong>BIOS</strong></a><strong>: </strong>Nucleus of Life Science Innovation 🚀</p><h4>JOBS</h4><ul><li><strong>BIOS Talent: </strong>Find Jobs @ Breakout TechBio Startups — <a href="https://jobs.bios.community/companies"><strong><em>Search Jobs</em></strong></a> 🚀</li><li><strong>Post Jobs: </strong>Add Your Startup to BIOS Talent — <a href="https://docs.google.com/forms/d/e/1FAIpQLScR_bLlCQ7Ie6bJ_HZ_dJ_LmuV3TsDEi-aNDC8N9GPz6psk1Q/viewform"><strong><em>Post Now</em></strong></a><strong><em> </em></strong>🎉</li><li><strong>Students:</strong> <a href="https://www.alix.vc/students">Join Alix Ventures Fellowship</a> — <a href="https://docs.google.com/forms/d/e/1FAIpQLSckliaB67e-W2o9cmSbRNPLKrBBmtAx_S6CiFufc6QwHSCWSg/viewform"><strong>J<em>oin Now</em></strong></a><em> </em>🧬</li><li><strong>BIOS Contributor:</strong><em> </em><a href="https://medium.com/bios-community/write-for-bios-guest-contributor-aff9fbe6e1e">Share Your Thought Leadership</a> — <a href="https://docs.google.com/forms/d/e/1FAIpQLSdGPtCdigoAu0ePKvsgcq08qPwRFWkKrHOjIQe7nCP5II_Xeg/viewform"><strong><em>Join Now</em></strong></a>🔬</li></ul><h4>CONTENT &amp; COMMUNITY</h4><ul><li><strong>BIOS Daily:</strong> Join <em>25K+</em> Subscribers Following TechBio — <a href="https://www.bios.community/content"><strong><em>Sign Up</em></strong></a><em> </em>🔥</li><li><strong>BIOS Insider: </strong>Premium TechBio Thought Leadership — <a href="https://bioscommunity.substack.com/"><strong><em>Sign Up</em></strong></a><strong> </strong>✨</li><li><strong>BIOS Commons: </strong><a href="https://medium.com/bios-community/introducing-bios-fostering-early-stage-healthcare-life-sciences-innovation-78c11dd57fff">World’s Largest <em>#TechBio </em>Community</a> — <a href="https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform"><strong><em>Join Now</em></strong></a><strong><em> </em></strong>🎉</li></ul><h4>INVEST</h4><ul><li><strong>BIOS Angels:</strong> <a href="https://medium.com/bios-community/introducing-bios-angels-worlds-1st-techbio-angel-syndicate-5faec24d8439">1st TechBio Angel Investing Syndicate </a>— <a href="https://docs.google.com/forms/d/e/1FAIpQLSe_0k-Ehi2uzTa_geqDm_B9kuRVWNyrvWSU7ch_5hqEKMoahg/viewform"><strong><em>Join Now</em></strong></a><strong><em> </em></strong>🌟</li><li><strong>Alix Limited: </strong>Invest in Breakout TechBio Startups — <a href="https://docs.google.com/forms/d/e/1FAIpQLSfqKG3fZOcXTtZTwKEk3wOvN0CyIIUBZkn-FFf5JhRHE1zW0Q/viewform"><strong><em>Learn More</em></strong></a><strong><em> </em></strong>🧠</li></ul><h4>By:</h4><p><a href="https://www.alix.vc/"><strong>Alix Ventures</strong></a><strong>: </strong>Supporting Early Stage Life Science Startups Engineering Biology to Drive Radical Advances in Human Health</p><p><strong>Calling All Innovators </strong>— <a href="/service/mailto:partners@alix.vc">Click to Reach Out</a> 🚀</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/770/0*8v5g5OpjHCEGqROA.png" /></figure><h4>Overview: 10 Questions to 10 Early Stage Venture Capitalists</h4><p>This topic series brings together perspectives across a variety of early-stage VC funds to help readers gain insight into what investors believe to be key to their growth and success. In our belief that perspectives should be well-rounded and not monopolistic, we chose to feature 10 different investors rather than to dive deep with just 1 or 2 individuals. We have a lot to learn from each other and hope that by sharing 10 unique viewpoints, we may all come to our own insights faster. Our posts will be organized by question and cover topics including investment criteria, portfolio support, industry trends, and general advice.</p><p><strong>We are honored to feature investors at:</strong></p><p><a href="https://www.boehringer-ingelheim-venture.com/about_us.php"><strong>Boehringer Ingelheim</strong></a><strong>, </strong><a href="https://www.breakout.vc/"><strong>Breakout Ventures</strong></a><strong>, </strong><a href="https://www.arkitektventures.com/"><strong>Arkitekt Ventures</strong></a><strong>, </strong><a href="https://www.timebioventures.com/"><strong>Time BioVentures</strong></a><strong>, </strong><a href="https://www.bcapgroup.com/"><strong>B Capital Group</strong></a><strong>, </strong><a href="https://www.nea.org/"><strong>NEA</strong></a><strong>, </strong><a href="https://www.bvp.com/"><strong>Bessemer Venture Partners</strong></a><strong>, </strong><a href="https://www.nfx.com/"><strong>NFX</strong></a><strong>, </strong><a href="https://www.notboring.co/"><strong>Not Boring</strong></a><strong>, </strong><a href="https://www.mayfield.com/"><strong>Mayfield Fund</strong></a><strong>, &amp; </strong><a href="https://www.alix.vc/"><strong>Alix Ventures</strong></a></p><p>In this final post, we recap the series, covering topics including investment criteria, portfolio support, industry trends, and general advice. There was a wealth of knowledge shared, not all of which fit in this summary.</p><h3>1</h3><blockquote>“What are the top 3 common traits of founders in your portfolio?”</blockquote><p><em>“Optimism, grit and humility. Making the choice to start a company of any sort is a bold pursuit, let alone when that company’s success depends on commercializing novel science at scale. So it requires a unique ability to have a definitive view of how to build the future, the perseverance to get there no matter how many times you’ve been knocked down, and the awareness to know when you need support.”</em></p><p><a href="https://www.linkedin.com/in/juliatmoore/"><strong><em>Julia Moore</em></strong></a><strong><em> </em></strong><em>— Co-Founder &amp; Managing Partner @ </em><a href="https://www.breakout.vc/"><strong><em>Breakout Ventures</em></strong></a></p><p><em>“Purposefulness</em><strong><em> </em></strong><em>— sense of urgency to build something that matters</em></p><p><em>Fearlessness — gumption to make the impossible possible amidst uncertainty and limited resources</em></p><p><em>Humility — hunger for advice and hiring people smarter than them”</em></p><p><a href="https://www.linkedin.com/in/widya-mulyasasmita-6663618/"><strong>Widya Mulyasasmita</strong></a> — Sr. Principal @<strong> </strong><a href="https://www.bcapgroup.com/"><strong>B Capital Group</strong></a></p><p><em>“Trust, teamwork, and excellence. Drug development is a long and winding road — for biotech founders, it isn’t a question of if there will be challenges, but rather when. We’re always looking for founders that have a strong internal compass and high integrity that we can trust to do the right thing for the company, employees, investors, and patients. Additionally, Biotech is a team sport. We look for founders that can assemble and manage great teams and who view investors as company-building partners. Finally, we are driven by opportunities to partner with founders exhibiting novel ideas and industry-transforming approaches — those who settle for nothing less than excellent.”</em></p><p><a href="https://www.linkedin.com/in/jclopez004/"><strong>J.C. Lopez</strong></a><strong> </strong>— Principal @ <a href="https://www.nea.org/"><strong>NEA</strong></a></p><h4>For more insights read — <a href="https://medium.com/bios-community/season-2-10-10-vc-series-top-portfolio-founder-traits-df38de9f2b19">Part 1: Top Portfolio Founder Traits</a></h4><h3>2</h3><blockquote>“How does your investment criteria change in a recessionary environment?”</blockquote><p><em>“I believe it takes an even higher level of conviction from a founder to take the risk and start a company in a recessionary environment. So my criteria doesn’t change much — I continue investing in the best founders that are building businesses with solid business models that can have a massive impact on healthcare.”</em></p><p><a href="https://www.linkedin.com/in/pavanchoksi/"><strong>Pavan Choksi </strong></a>— Partner @ <a href="https://www.arkitektventures.com/"><strong>Arkitekt Ventures</strong></a></p><p><em>“The goal of identifying the best companies will not change. We’ve always been focused on business model fundamentals and efficiency and I’m glad the conversation is broadly shifting this way. I recently studied 52 public and private companies to understand fundamentally what KPIs were best in class vs average in digital health (Learn more </em><a href="https://www.bvp.com/atlas/benchmarks-for-growing-health-tech-businesses/?from=feature"><em>here</em></a><em>). We are hoping to change how these companies are valued to match how efficient and scalable the different business models can be.”</em></p><p><a href="https://www.linkedin.com/in/sofia-guerra-33491647/"><strong>Sofia Guerra</strong></a><strong> </strong>— Investor @ <a href="https://www.bvp.com/"><strong>Bessemer Venture Partners</strong></a></p><p><em>“At Not Boring, Packy and I spend a lot of time thinking about the big opportunities opened up by the current macro environment. We have conviction that it’s a great time to build </em><a href="https://www.notboring.co/p/the-good-thing-about-hard-things"><em>Hard Startups</em></a><em> that do ambitious things in the physical world. In other words, the biggest returns will come from a return to the basics of venture capital, where fortunes were made financing truly frontier technology like semiconductors and computer networks.”</em></p><p><a href="https://www.linkedin.com/in/elliot-hershberg/"><strong>Elliot Hershberg </strong></a>— Partner @ <a href="https://www.notboring.co/"><strong>Not Boring</strong></a></p><h4>For more insights read — Part 2: <a href="https://medium.com/bios-community/season-2-10-10-vc-series-raising-capital-in-down-markets-7ab6a6a06ef3">Raising Capital in Down Markets</a></h4><h3>3</h3><blockquote>“How has your worldview evolved since you first started your VC career?”</blockquote><p><em>“At the risk of sounding cheesy, the biggest waves can be started by the smallest pebble. By that I mean seemingly small ideas can have a huge impact. I do this job to work with multiple teams with one goal in mind, novel, approved medicines. If you get there, the rest of it takes care of itself. Watching the earliest stage ideas mature and evolve into drugs is the coolest think about biotech VC.”</em></p><p><a href="https://www.linkedin.com/in/kanad-das-b51924b/"><strong>Kanad Das</strong> </a>— Investment Director @ <a href="https://www.boehringer-ingelheim-venture.com/about_us.php"><strong>Boehringer Ingelheim</strong></a></p><p><em>“I would say I’m much more optimistic! A career in VC forces you to ask yourself — what if this idea works? On a daily basis I get exposed to new approaches to make healthcare or medicine better and I’m so fortunate that I get to spend my time with founders that make me ask questions to imagine a future where they realize their vision: What if this care delivery model can help kids access better mental health treatment? What if this technology helps discover a new cancer drug?”</em></p><p><a href="https://www.linkedin.com/in/pavanchoksi/"><strong>Pavan Choksi</strong> </a>— Partner @ <a href="https://www.arkitektventures.com/"><strong>Arkitekt Ventures</strong></a></p><p><em>“You learn how to be more selective. Seeing more deals helps your pattern recognition. You get to see that great IP and technology is not enough. The quality of the founding team is crucial. I would rather have mediocre technology with an incredible team, than an incredible technology with a mediocre team.”</em></p><p><a href="https://www.linkedin.com/in/omri-amirav-drory-50572727/"><strong>Omri Amirav-Drory</strong></a> — General Partner @ <a href="https://www.nfx.com/"><strong>NFX</strong></a></p><h4>For more insights read — <a href="https://medium.com/bios-community/season-2-10-10-vc-series-worldview-changes-since-starting-vc-career-5e2161d45952">Part 3: Worldview Changes Since Starting VC Career</a></h4><h3>4</h3><blockquote>“Outside of operating experience &amp; higher education, what is one seemingly random thing you look for in a founder’s background?”</blockquote><p><em>“Leadership through emotional intelligence and empathy. Being a founder/C-suite team member is hard and the ability to stay humble, data driven, understanding of human emotion leads to high functioning teams. This is a people business at the end of the day and in my experience a strong team that asks the right questions and does the right experiments has the greatest chance at success.”</em></p><p><a href="https://www.linkedin.com/in/kanad-das-b51924b/"><strong>Kanad Das </strong></a>— Investment Director @ <a href="https://www.boehringer-ingelheim-venture.com/about_us.php"><strong>Boehringer Ingelheim</strong></a></p><p><em>“I’m particularly excited to meet founders who have been outsiders or underdogs and have worked incredibly hard to turn those odds around. It can be small examples from your upbringing or what you’ve done to alter the status quo. I left my home in Guatemala alone when I was 17 because I was searching for better opportunities to pursue science and excellence in education. I defied the stereotype that little girls couldn’t study science or live alone to follow their dreams. I look for a spark in founders that will drive them to break through walls to achieve their goals.”</em></p><p><a href="https://www.linkedin.com/in/sofia-guerra-33491647/"><strong>Sofia Guerra</strong></a> — Investor @ <a href="https://www.bvp.com/"><strong>Bessemer Venture Partners</strong></a></p><h4>For more insights read — <a href="https://medium.com/bios-community/season-2-10-10-vc-series-preferred-founder-backgrounds-8aa384a840ea">Part 4: Preferred Founder Backgrounds</a></h4><h3>5</h3><blockquote>“Outside of investing, what is one seemingly random activity that helps make you a better VC?”</blockquote><p><em>“Nature walks with folks who aren’t traditionally in VC. For instance, I love walking with scientists and professors. The mix of fresh conversations, exercise, and being outdoors has a generative power to spark great ideas and new ways to spot innovation trends.”</em></p><p><a href="https://www.linkedin.com/in/widya-mulyasasmita-6663618/">Widya Mulyasasmita</a> — Sr. Principal @ <a href="https://www.bcapgroup.com/">B Capital Group</a></p><p><em>“Well before I worked in VC — or even did science — I spent a team of time reading fiction and poetry. I actually published works of poetry before I ever published a scientific paper! While at first it doesn’t seem related, I think this focus on language has helped for the unique path I’ve taken into venture with such a specific focus on writing and storytelling. This is a unique way that we partner with founders and concretely provide value at Not Boring.”</em></p><p><a href="https://www.linkedin.com/in/elliot-hershberg/"><strong>Elliot Hershberg</strong> </a>— Partner @ <a href="https://www.notboring.co/"><strong>Not Boring</strong></a></p><h4>For more insights read — <a href="https://medium.com/bios-community/season-2-10-10-vc-series-growth-mindset-f286edb5adac">Part 5: Growth Mindset</a></h4><h3>6</h3><blockquote>“What has been the most helpful piece of advice you received throughout your career as a venture capitalist?”</blockquote><p><em>“‘Don’t lose sight of the forest for a leaf’ — when assessing an opportunity there is always another question you’ll want to ask but always focusing on the bigger picture has made me a better investor and partner to founders.”</em></p><p><a href="https://www.linkedin.com/in/pavanchoksi/"><strong>Pavan Choksi </strong></a>— Partner @ <a href="https://www.arkitektventures.com/"><strong>Arkitekt Ventures</strong></a></p><p><em>“Do the work (calls, analysis, review docs) and trust your intuition. You’ve done the work to build conviction.</em></p><p><em>There are multiple investing styles, try to find what is true to you vs trying to become someone else.”</em></p><p><a href="https://www.linkedin.com/in/sofia-guerra-33491647/"><strong><em>Sofia Guerra</em></strong></a><strong><em> </em></strong><em>— Investor @</em><strong><em> </em></strong><a href="https://www.bvp.com/"><strong><em>Bessemer Venture Partners</em></strong></a></p><p><em>“Don’t invest for the first 9 months as a VC. It takes time to recognize what makes a successful company. You need that time to really see a lot of companies, to see what the best companies have in common and once you’ve started to build that pattern recognition you can start investing.”</em></p><p><a href="https://www.linkedin.com/in/omri-amirav-drory-50572727/"><strong>Omri Amirav-Drory</strong></a> — General Partner @ <a href="https://www.nfx.com/">NFX</a></p><h4>For more insights read — <a href="https://medium.com/bios-community/season-2-10-10-vc-series-best-career-advice-8e294ebc0244">Part 6: Best Career Advice</a></h4><h3>7</h3><blockquote>“As an early stage investor, we often pick companies whose directions change. Can you talk about pivoting vs. staying the course?”</blockquote><p><em>“If done well, early stage is a constant iteration of taking in new data and slightly adjusting the trajectory. That may mean you end up somewhere entirely different than you thought at seed, but less often as the result of a sharp left turn. To some extent that is even true in seemingly immovable trajectories like therapeutics where you can adjust your pipeline or how you approach preclinical data. Staying the course blindly feels like an outdated concept — the pace of innovation is so incredibly fast, the reality you are operating in today is inherently different than the one you built your business plan in.”</em></p><p><a href="https://www.linkedin.com/in/juliatmoore/"><strong>Julia Moore</strong></a><strong> </strong>— Co-Founder &amp; Managing Partner @ <a href="https://www.breakout.vc/"><strong>Breakout Ventures</strong></a></p><p><em>“Companies are like organisms, and their success comes from finding niches in their environments. The key is to “listen” to the environment and respond to it. Sometimes, this means pivoting and other times it means doubling down. The key is to ground these choices in rational consideration.”</em></p><p><a href="https://www.linkedin.com/in/dawallach/"><strong>D.A. Wallach</strong></a> — Co-Founder &amp; General Partner @ <a href="https://www.timebioventures.com/"><strong>Time BioVentures</strong></a></p><p><em>“Product market fit is learned, not divined. Pivoting is a way of finding product market fit through experience. In capex heavy companies, the key is to find ways of discovering PMF without incurring heavy costs. Great founder-product fit results in fewer pivots. This is why we at Mayfield back people first, markets second.”</em></p><p><a href="https://www.linkedin.com/in/arvndgpta/"><strong>Arvind Gupta</strong></a><strong> </strong>— Partner @ <a href="https://www.mayfield.com/"><strong>Mayfield Fund</strong></a></p><h4>For more insights read — <a href="https://medium.com/bios-community/season-2-10-10-vc-series-pivoting-vs-persisting-b2700e2db46c">Part 7: Pivoting vs. Persisting</a></h4><h3>8</h3><blockquote>“How do you advise founders in your portfolio to prepare ahead of time for future fundraises?”</blockquote><p><em>“Being a founder (particularly a first time founder) means you’re doing something you’ve never done before. That means you’re likely rather uncomfortable. Knowledge can assuage some of that discomfort. Successful founders find creative ways of finding an answer, and a lot of the time it just means picking up the phone. I strongly advise founders to talk to their peers, their board, other partners at the funds who gave them money, their networks and the independent/chair. I can’t overemphasize the concept of group think when it comes to these things. When I was a grad student, my Ph.D. advisor would always say that an afternoon in the library saves a month in the lab. In this case, a few zoom calls can save a lot of time and money. I would suggest that founders start with the Board (it’s our job after all!) and then expand.”</em></p><p><a href="https://www.linkedin.com/in/kanad-das-b51924b/"><strong>Kanad Das</strong> </a>— Investment Director @ <a href="https://www.boehringer-ingelheim-venture.com/about_us.php"><strong>Boehringer Ingelheim</strong></a></p><p><em>“In my experience, if you’re courageous enough to ask for help, most people are willing to give it. We all started at the bottom and remember what it was like to be there.”</em></p><p><a href="https://www.linkedin.com/in/omri-amirav-drory-50572727/"><strong>Omri Amirav-Drory</strong></a> — General Partner @ <a href="https://www.nfx.com/"><strong>NFX</strong></a></p><p><em>“Find the best people in your field and surround yourself with them. Learn from their experiences. Become their friends. Life is not a transaction and mentorship isn’t either. Great mentor relationships come from two-way streets of inspiration.”</em></p><p><a href="https://www.linkedin.com/in/arvndgpta/"><strong><em>Arvind Gupta</em></strong></a><strong><em> </em></strong><em>— Partner @ </em><a href="https://www.mayfield.com/"><strong><em>Mayfield Fund</em></strong></a></p><h4>For more insights read — <a href="https://medium.com/bios-community/season-2-10-10-vc-series-advice-for-founders-seeking-mentorship-79b45f751be8">Part 8: Advice for Founders Seeking Mentorship</a></h4><h3>9</h3><blockquote>“How does your evaluation process change when it comes to backing first-time vs. repeat founders?”</blockquote><p><em>“You are looking for those same traits — optimism, grit and humility — that can exist in a founder whether it is your first company or your fifth. The more experience a founder has, the easier it will be to spot those traits as you simply have more data to go off of. In a first time founder, you need to read between the lines a bit more. To that end, we look for founders who are able to recruit great talent to their vision from day one and who never feel threatened that they will be hiring people much smarter or more experienced than them in one way or the other.”</em></p><p><a href="https://www.linkedin.com/in/juliatmoore/"><strong>Julia Moore</strong></a><strong> </strong>— Co-Founder &amp; Managing Partner @ <a href="https://www.breakout.vc/"><strong>Breakout Ventures</strong></a></p><p><em>“We are equally receptive to both first-time and repeat founders. There are trade-offs associated with both founder phenotypes. First-time founders are typically closer to the science/engineering, and have a lot of energy and vision. By definition, they have less entrepreneurial experience. This can make the choice of investors and advisors more important.</em></p><p><em>We’re also excited by founders who led in technical roles at larger biotechs and biopharmas, and are leaving to solve pressing problems in the industry that they have direct experience with.”</em></p><p><a href="https://www.linkedin.com/in/elliot-hershberg/"><strong>Elliot Hershberg </strong></a>— Partner @ <a href="https://www.notboring.co/"><strong>Not Boring</strong></a></p><h4>For more insights read — <a href="https://medium.com/bios-community/season-2-10-10-vc-series-first-time-vs-repeat-founders-8bf4f9f5b2d0">Part 9: First-time vs. Repeat Founders</a></h4><h3>10</h3><blockquote>“As a founder building something new in the world, you are often in need of knowledge you don’t possess. How would you recommend founders go about seeking mentorship?”</blockquote><p><em>“I could write about this for many paragraphs, but like anything, a clear story and ask is the key. I firmly believe that science determines the contours of a deal so I would suggest that they are as open as they can be about the data they have, the risks, and the time/money to a meaningful value inflection point. I would then take the story to a small number of known, trusted and experienced people to ask for feedback. While you likely won’t get consistent messages, the key is to listen to where people feel ‘the story falls apart.’ Take that feedback seriously and try to incorporate it into your deck.”</em></p><p><a href="https://www.linkedin.com/in/kanad-das-b51924b/"><strong>Kanad Das</strong> </a>— Investment Director @ <a href="https://www.boehringer-ingelheim-venture.com/about_us.php"><strong>Boehringer Ingelheim</strong></a></p><p><em>“Let us in early. We have seen thousands of pitches and know how to spot a good deck. Let your investors help you and give feedback on the story and the flow.”</em></p><p><a href="https://www.linkedin.com/in/omri-amirav-drory-50572727/"><strong>Omri Amirav-Drory</strong></a><strong> </strong>— General Partner @ <a href="https://www.nfx.com/"><strong>NFX</strong></a></p><h4>For more insights read — Part 10: <a href="https://medium.com/bios-community/season-2-10-10-vc-series-preparing-for-future-fundraising-46bb99014e94">Preparing for Future Fundraising</a></h4><p>📣 <strong>If you enjoyed this post please clap 👏 &amp; comment </strong>💬 <strong>to let us know</strong></p><p><em>Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement or recommendation by Alix Ventures, BIOS Community, or its affiliates. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by Alix Ventures employees are those of the employees and do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, and content sponsors.</em></p><h4>Join BIOS Community 🎉</h4><p>Become a member, continue the conversation, connect with like-minded Life Science innovators, access exclusive resources, &amp; invite-only events…</p><p><strong>Apply to Join — </strong><a href="https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform"><strong>Membership Application</strong></a></p><h4>For More Interesting Content 💭</h4><p>🧬 <strong>Podcast</strong> — <a href="https://open.spotify.com/show/2HmcPq9k8fYpn60F3hw6Ra?si=Qk9UeVGUSQajclaTYzN2uQ">Stream Full Episodes</a></p><p>🧪 <strong>YouTube </strong>— <a href="https://www.youtube.com/channel/UCWadRaYPrE1kE4t9LuCd28w">Watch Videos</a></p><p>🩺<strong> Twitter </strong>— <a href="https://twitter.com/bios_community">Explore Feed</a></p><p>🦠 <strong>LinkedIn</strong> — <a href="https://www.linkedin.com/company/bios-community">Read Posts</a></p><h4>Subscribe to BIOS Newsletter for special content: <a href="https://www.bios.community/content">Click Here</a> 🔥</h4><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=388afdf4ac72" width="1" height="1" alt=""><hr><p><a href="https://medium.com/bios-community/recap-season-2-10-10-vc-series-388afdf4ac72">Recap — Season 2: 10/10 VC Series</a> was originally published in <a href="https://medium.com/bios-community">BIOS Community</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[10 Questions w/ Gene Yeo — Professor @ UCSD]]></title>
            <link>https://medium.com/bios-community/10-questions-w-gene-yeo-professor-ucsd-62fd7f2dfec6?source=rss-183f327fce8c------2</link>
            <guid isPermaLink="false">https://medium.com/p/62fd7f2dfec6</guid>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[academia]]></category>
            <category><![CDATA[founders]]></category>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[biology]]></category>
            <dc:creator><![CDATA[BIOS]]></dc:creator>
            <pubDate>Thu, 04 May 2023 04:16:05 GMT</pubDate>
            <atom:updated>2023-06-22T04:46:12.489Z</atom:updated>
            <content:encoded><![CDATA[<h3>10 Questions w/ Gene Yeo — Professor @ UCSD</h3><p><a href="https://www.bios.community/"><strong>BIOS</strong></a><strong>: </strong>Nucleus of Life Science Innovation 🚀</p><p><strong>JOBS</strong></p><ul><li><strong>BIOS Talent: </strong>Find Jobs @ Breakout TechBio Startups — <a href="https://jobs.bios.community/companies"><strong><em>Search Jobs</em></strong></a> 🚀</li><li><strong>Post Jobs: </strong>Add Your Startup to BIOS Talent — <a href="https://docs.google.com/forms/d/e/1FAIpQLScR_bLlCQ7Ie6bJ_HZ_dJ_LmuV3TsDEi-aNDC8N9GPz6psk1Q/viewform"><strong><em>Post Now</em></strong></a><strong><em> </em></strong>🎉</li><li><strong>Students:</strong> <a href="https://www.alix.vc/students">Join Alix Ventures Fellowship</a> — <a href="https://docs.google.com/forms/d/e/1FAIpQLSckliaB67e-W2o9cmSbRNPLKrBBmtAx_S6CiFufc6QwHSCWSg/viewform"><strong>J<em>oin Now</em></strong></a><em> </em>🧬</li><li><strong>BIOS Contributor:</strong><em> </em><a href="https://medium.com/bios-community/write-for-bios-guest-contributor-aff9fbe6e1e">Share Your Thought Leadership</a> — <a href="https://docs.google.com/forms/d/e/1FAIpQLSdGPtCdigoAu0ePKvsgcq08qPwRFWkKrHOjIQe7nCP5II_Xeg/viewform"><strong><em>Join Now</em></strong></a></li></ul><p><strong>CONTENT &amp; COMMUNITY</strong></p><ul><li><strong>BIOS Daily:</strong> Join <em>25K+</em> Subscribers Following TechBio — <a href="https://www.bios.community/content"><strong><em>Sign Up</em></strong></a><em> </em>🔥</li><li><strong>BIOS Insider: </strong>Premium TechBio Thought Leadership — <a href="https://bioscommunity.substack.com/"><strong><em>Sign Up</em></strong></a><strong> </strong>✨</li><li><strong>BIOS Commons: </strong><a href="https://medium.com/bios-community/introducing-bios-fostering-early-stage-healthcare-life-sciences-innovation-78c11dd57fff">World’s Largest <em>#TechBio </em>Community</a> — <a href="https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform"><strong><em>Join Now</em></strong></a><strong><em> </em></strong>🎉</li></ul><p><strong>INVEST</strong></p><ul><li><strong>BIOS Angels:</strong> <a href="https://medium.com/bios-community/introducing-bios-angels-worlds-1st-techbio-angel-syndicate-5faec24d8439">1st TechBio Angel Investing Syndicate </a>— <a href="https://docs.google.com/forms/d/e/1FAIpQLSe_0k-Ehi2uzTa_geqDm_B9kuRVWNyrvWSU7ch_5hqEKMoahg/viewform"><strong><em>Join Now</em></strong></a><strong><em> </em></strong>🌟</li><li><strong>Alix Limited: </strong>Invest in Breakout TechBio Startups — <a href="https://docs.google.com/forms/d/e/1FAIpQLSfqKG3fZOcXTtZTwKEk3wOvN0CyIIUBZkn-FFf5JhRHE1zW0Q/viewform"><strong><em>Learn More</em></strong></a><strong><em> </em></strong>🧠</li></ul><p><strong>By:</strong></p><p><a href="https://www.alix.vc/"><strong>Alix Ventures</strong></a><strong>: </strong>Supporting Early Stage Life Science Startups Engineering Biology to Drive Radical Advances in Human Health</p><p><strong>Calling All Innovators </strong>— <a href="/service/mailto:partners@alix.vc">Click to Reach Out</a> 🚀</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*vznqvHOkX4D1gRU7MN4RMw.png" /></figure><p><a href="https://www.linkedin.com/in/geneyeo/"><strong><em>Gene Yeo</em></strong></a><strong><em> </em></strong><em>is a Professor of Cellular &amp; Molecular Medicine @ The University of California San Diego (UCSD), a founding member of the Institute for Genomic Medicine and member of the UCSD Stem Cell Program and Moores Cancer Center. Dr. Yeo has a BSc in Chemical Engineering and a BA in Economics from the University of Illinois, Urbana-Champaign, a Ph.D. in Computational Neuroscience from Massachusetts Institute of Technology and an MBA from the UCSD Rady School of Management.</em></p><p><em>Yeo is a computational and experimental scientist who has contributed to RNA biology and therapeutics. His primary research interest is in understanding the importance of RNA processing and the roles that RNA binding proteins (RBPs) play in development and disease. Since inception, Yeo’s lab has focused on uncovering molecular principles by which RBPs affect gene expression, how RBP- mediated post-transcriptional gene networks contribute to cellular homeostasis in stem cells and the brain, and how mutations in RBPs lead to human developmental and neurodegenerative disease. His lab pioneered computational algorithms and experimental methods in human disease-relevant systems to conduct systematic and large-scale studies. These multidisciplinary methods combine machine learning, biochemistry, molecular biology, genomics, chemistry and materials research. His lab develops methods that are systematic, robust and adoptable, such as enhanced CLIP for the purposes of large-scale mapping of protein-RNA interactions (Van Nostrand et al, Nature Methods, 2016). Gene’s lab is a major contributor of resources to study RBPs that enable hundreds of labs across many areas of bioscience, such as the world’s largest resource of RBP-specific antibodies that facilitated generation and interpretation of the most comprehensive maps of RBP-binding sites to date for hundreds of RBPs (Van Nostrand et al, Nature, 2020). They have also systematically uncovered RBPs that condense into RNA granules during stress and demonstrated strategies to leverage these for therapeutic use in neurodegeneration (Markmiller et al, Cell, 2018; Fang et al, Neuron, 2019; Wheeler et al, Nature Methods, 2020). His lab also demonstrated in vivo RNA targeting with CRISPR/Cas proteins (Nelles et al, Cell, 2016) with proof of concept in repeat expansion disorders (Batra et al, Cell, 2017; Batra et al, Nature Biomedical Engineering, 2020). Work from the Yeo lab has been highlighted in Nature Methods and Nature Reviews Genetics as “Method to Watch” and featured as a top story in Discover magazine in 2016. These efforts have led to clinical programs to develop medicines for RNA-related diseases.</em></p><p><em>Yeo has authored more than 200 peer-reviewed publications including invited book chapters and review articles in the areas of neurodegeneration, RNA processing, computational biology and stem cell models; and served as Editor on two books on the biology of RNA binding proteins. Gene is on the Editorial Boards of the journals Cell Reports, Cell Research and eLife, and on the Advisory Board of Review commons. Gene joined UCSD as an Assistant Professor in 2008, was promoted with tenure to Associate Professor in 2014 and to Professor in 2016. Gene was the first Crick-Jacobs Fellow at the Salk Institute (2005–2008) and is a recipient of the Alfred P Sloan Fellowship in recognition of his work in computational molecular biology (2011), Alpha Chi Sigma-Zeta Chapter Krug Lecturer (2016), Singapore National Research Foundation Visiting Investigatorship Award (2017), the inaugural Early Career Award from the International RNA Society (2017), the Blavatnik National Award Finalist (2018 &amp; 2019), San Diego Xconomy Awardee for ‘Big Idea’ (2019) and 2019 recipient of the Highly Cited Researcher in Cross-Field category, recognizing the world’s most influential researchers of the past decade. Gene’s research has been funded by the National Institute of Health, National Science Foundation, California Institute for Regenerative Medicine, TargetALS, ALS Foundation, Department of Defense, Myotonic Dystrophy Association, Myotonic Dystrophy Foundation and Chan-Zuckerberg Initiative. Gene has also been funded and collaborates with biotech and pharmaceutical companies such as Takeda, Genentech and Roche.</em></p><p><em>Gene is a co-founder of biotech companies which includes Locana, Eclipse Bioinnovations, Enzerna, Proteona (acquired by Singleron) and Orbital Therapeutics. Gene played a critical role in the successful raising of $55M for Locana at series A (2019). Gene serves or had served on the scientific advisory boards of the Allen Institute of Immunology, Locana, Eclipse Bioinnovations, Proteona, Aquinnah, Cell Applications, Nugen (now Tecan), Sardona Therapeutics and Ribometrix. Gene is a senior advisor to Accelerator Life Sciences Partners.</em></p><p><em>Gene is the faculty founder of DASL (Diversity and Science Lecture Series, 2020) providing a voice for scientists to discuss diversity, equity and inclusion challenges and celebrating their scientific achievements. Gene was a Sword of Honor recipient (the highest honor) in Officer Cadet School in 1999 and has served in the Singapore Navy as a Naval officer. Gene has completed 2 full Ironman-distance and multiple half-ironman-, olympic-, sprint-distance triathlons, full marathons and half-marathons, but now spends time rock climbing.</em></p><h4>We sat down with Gene Yeo to ask his viewpoints on everything from entrepreneurial lab culture, what he looks for in new research topics, to advice on building companies…</h4><h4>1</h4><h4>What advice would you give to founders working with University Tech Transfer looking to spinout out a company?</h4><blockquote>“University Tech Transfer can be an exceptional partner to amplify the value of research findings. My advice is to work closely with tech transfer on carefully timing the publications with the disclosures.”</blockquote><h4>2</h4><h4>Can you describe your process for vetting new ideas to pursue in your lab?</h4><blockquote>“I look for the intersection of strong technology opportunity, strong biology and then identify strong trainees that can marry the two.“</blockquote><h4>3</h4><h4>How do you establish an effective entrepreneurial lab culture?</h4><blockquote>“Promote risk-taking and build multi-disciplinary teams”</blockquote><h4>4</h4><h4>What advice would you give to professors trying to entrepreneurialize their labs?</h4><blockquote>“As an academic mentor, I try as much as possible to identify projects that fulfill both an academic mission by solving fundamental questions and also form opportunities for trainees to gain valuable skill sets and if successful, create commercial and career opportunities for the trainees and the lab“</blockquote><h4>5</h4><h4>Outside of academia, what is one seemingly random activity that helps make you a better researcher?</h4><blockquote>“Family. Family centers my worldview and forces me to be much more efficient with my time“</blockquote><h4>6</h4><h4>How do you identify the point at which a scientific discovery is ripe for commercialization?</h4><blockquote>“Personally, I do not think I do a good job identifying these points, but I try to work with the best people in the business to help me strategize and act as reality checks. That would be my advice, work with folks with much more experience than you. “</blockquote><h4>7</h4><h4>What advice can you give to academics raising their first round of venture funding?</h4><blockquote>“My advice is that it is important to identify venture partners that have more value to add than just capital. Different technologies need different amounts of runway and time to mature and not all venture firms have the same patience. Some technologies need a mixture of young academic teams and seasoned biotech managers to give them a chance and some investors understand that.</blockquote><h4>8</h4><h4>What advice would you give to business professionals looking to get in contact/help commercialize startups spinning out of academia?</h4><blockquote>“I believe it is helpful to have strong personal as well as professional relationships with the academic founders of the concepts and technologies that business professionals hope to leverage. My advice to business professionals would be to identify academic founders that are true, dependable partners.“</blockquote><h4>9</h4><h4>What advice would you give to professors in balancing founding a company and continuing to pursue academic research?</h4><blockquote>“My advice would be to prioritize your academic lines of inquiry as companies need to be very focused and narrow and as such they may be blindsided by the next generation of research. Founding companies can nevertheless be rewarding for your trainees and your academic ecosystem“</blockquote><h4>10</h4><h4>What has been the most helpful piece of advice you received throughout your career as an academic entrepreneur?</h4><blockquote>“NO one is irreplaceable.”</blockquote><p>📣 <strong>If you enjoyed this post please clap 👏 &amp; comment </strong>💬 <strong>to let us know</strong></p><p>❤️ Thanks <a href="https://medium.com/u/d4a12fd97637?source=post_page-----1b4f1f3e5213-----------------------------------"><strong>Andrew Yashar</strong></a> for your help in putting this together :)</p><h3>Join BIOS Community 🎉</h3><p>Become a member, continue the conversation, connect with like-minded Life Science innovators, access exclusive resources, &amp; invite-only events…</p><p><strong>Apply to Join — </strong><a href="https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform"><strong>Membership Application</strong></a></p><h3>For More Interesting Content 💭</h3><p>🧬 <strong>Podcast</strong> — <a href="https://open.spotify.com/show/2HmcPq9k8fYpn60F3hw6Ra?si=Qk9UeVGUSQajclaTYzN2uQ">Stream Full Episodes</a></p><p>🧪 <strong>YouTube </strong>— <a href="https://www.youtube.com/channel/UCWadRaYPrE1kE4t9LuCd28w">Watch Videos</a></p><p>🩺<strong> Twitter </strong>— <a href="https://twitter.com/bios_community">Explore Feed</a></p><p>🦠 <strong>LinkedIn</strong> — <a href="https://www.linkedin.com/company/bios-community">Read Posts</a></p><p><strong>Subscribe to BIOS Newsletter for special content: </strong><a href="https://www.bios.community/content"><strong>Click Here</strong></a><strong> 🔥</strong></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=62fd7f2dfec6" width="1" height="1" alt=""><hr><p><a href="https://medium.com/bios-community/10-questions-w-gene-yeo-professor-ucsd-62fd7f2dfec6">10 Questions w/ Gene Yeo — Professor @ UCSD</a> was originally published in <a href="https://medium.com/bios-community">BIOS Community</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[10 Questions w/ Chad Mirkin — Professor @ Northwestern]]></title>
            <link>https://medium.com/bios-community/10-questions-w-chad-mirkin-professor-northwestern-db47fefa769d?source=rss-183f327fce8c------2</link>
            <guid isPermaLink="false">https://medium.com/p/db47fefa769d</guid>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[science]]></category>
            <category><![CDATA[academia]]></category>
            <category><![CDATA[biology]]></category>
            <dc:creator><![CDATA[BIOS]]></dc:creator>
            <pubDate>Mon, 01 May 2023 05:18:53 GMT</pubDate>
            <atom:updated>2023-05-04T04:29:34.030Z</atom:updated>
            <content:encoded><![CDATA[<h3>10 Questions w/ Chad Mirkin — Professor @ Northwestern</h3><p><a href="https://www.bios.community/"><strong>BIOS</strong></a><strong>: </strong>Nucleus of Life Science Innovation 🚀</p><p><strong>JOBS</strong></p><ul><li><strong>BIOS Talent: </strong>Find Jobs @ Breakout TechBio Startups — <a href="https://jobs.bios.community/companies"><strong><em>Search Jobs</em></strong></a> 🚀</li><li><strong>Post Jobs: </strong>Add Your Startup to BIOS Talent — <a href="https://docs.google.com/forms/d/e/1FAIpQLScR_bLlCQ7Ie6bJ_HZ_dJ_LmuV3TsDEi-aNDC8N9GPz6psk1Q/viewform"><strong><em>Post Now</em></strong></a><strong><em> </em></strong>🎉</li><li><strong>Students:</strong> <a href="https://www.alix.vc/students">Join Alix Ventures Fellowship</a> — <a href="https://docs.google.com/forms/d/e/1FAIpQLSckliaB67e-W2o9cmSbRNPLKrBBmtAx_S6CiFufc6QwHSCWSg/viewform"><strong>J<em>oin Now</em></strong></a><em> </em>🧬</li><li><strong>BIOS Contributor:</strong><em> </em><a href="https://medium.com/bios-community/write-for-bios-guest-contributor-aff9fbe6e1e">Share Your Thought Leadership</a> — <a href="https://docs.google.com/forms/d/e/1FAIpQLSdGPtCdigoAu0ePKvsgcq08qPwRFWkKrHOjIQe7nCP5II_Xeg/viewform"><strong><em>Join Now</em></strong></a></li></ul><p><strong>CONTENT &amp; COMMUNITY</strong></p><ul><li><strong>BIOS Daily:</strong> Join <em>25K+</em> Subscribers Following TechBio — <a href="https://www.bios.community/content"><strong><em>Sign Up</em></strong></a><em> </em>🔥</li><li><strong>BIOS Insider: </strong>Premium TechBio Thought Leadership — <a href="https://bioscommunity.substack.com/"><strong><em>Sign Up</em></strong></a><strong> </strong>✨</li><li><strong>BIOS Commons: </strong><a href="https://medium.com/bios-community/introducing-bios-fostering-early-stage-healthcare-life-sciences-innovation-78c11dd57fff">World’s Largest <em>#TechBio </em>Community</a> — <a href="https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform"><strong><em>Join Now</em></strong></a><strong><em> </em></strong>🎉</li></ul><p><strong>INVEST</strong></p><ul><li><strong>BIOS Angels:</strong> <a href="https://medium.com/bios-community/introducing-bios-angels-worlds-1st-techbio-angel-syndicate-5faec24d8439">1st TechBio Angel Investing Syndicate </a>— <a href="https://docs.google.com/forms/d/e/1FAIpQLSe_0k-Ehi2uzTa_geqDm_B9kuRVWNyrvWSU7ch_5hqEKMoahg/viewform"><strong><em>Join Now</em></strong></a><strong><em> </em></strong>🌟</li><li><strong>Alix Limited: </strong>Invest in Breakout TechBio Startups — <a href="https://docs.google.com/forms/d/e/1FAIpQLSfqKG3fZOcXTtZTwKEk3wOvN0CyIIUBZkn-FFf5JhRHE1zW0Q/viewform"><strong><em>Learn More</em></strong></a><strong><em> </em></strong>🧠</li></ul><p><strong>By:</strong></p><p><a href="https://www.alix.vc/"><strong>Alix Ventures</strong></a><strong>: </strong>Supporting Early Stage Life Science Startups Engineering Biology to Drive Radical Advances in Human Health</p><p><strong>Calling All Innovators </strong>— <a href="/service/mailto:partners@alix.vc">Click to Reach Out</a> 🚀</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*5caHBXLwZwRlLLV4TsOFGg.png" /></figure><p><strong><em>Chad Mirkin</em></strong><em> is the Director of the International Institute for Nanotechnology and the George B. Rathmann Prof. of Chemistry, Prof. of Chemical and Biological Engineering, Prof. of Biomedical Engineering, Prof. of Materials Science &amp; Engineering, and Prof. of Medicine at Northwestern University.</em></p><p><em>He is a chemist and a world-renowned nanoscience expert, who is known for his discovery and development of spherical nucleic acids (SNAs) and SNA-based biodetection and therapeutic schemes, the invention of Dip-Pen Nanolithography (DPN) and related cantilever-free nanopatterning methodologies, On-Wire Lithography (OWL), Co-Axial Lithography (COAL), and contributions to supramolecular chemistry and nanoparticle synthesis. He is the author of over 850 manuscripts and over 1,200 patent applications worldwide (over 400 issued), and the founder of multiple companies, including Nanosphere, AuraSense, TERA-print, Azul 3D, MattIQ, and Flashpoint Therapeutics.</em></p><p><em>Mirkin has been recognized for his accomplishments with over 250 national and international awards. These include the King Faisal Prize in Science, the Faraday Medal, UNESCO-Equatorial Guinea International Prize for Research in Life Sciences, Kabiller Prize in Nanoscience and Nanomedicine, the SCI Perkin Medal, Friendship Award, Nano Research Award, AAAS Philip Hauge Abelson Award, Richards Award and Medal, Harrison Howe Award, the Remsen Award, Ralph N. Adams Award, the Dickson Prize in Science, the RUSNANOPRIZE, the Nichols Medal, the 2016 Dan David Prize, the inaugural NAS Sackler Prize in Convergence Research, the RSC Centenary Prize, the Friends of the National Library of Medicine Distinguished Medical Science Award, the 2014 National Security Science and Engineering Fellowship (NSSEFF) Award, the 2014 Thomson Reuters Highly Cited Researcher (2002–2012), the ACS Nano Lectureship Award for the Americas, the Vittorio deNora Award (The Electrochemical Society), the Linus Pauling Medal, the Thomson Reuters “Nobel-Class” Citation Laureate, RSC’s “Chemistry World” Entrepreneur of the Year Award, a Honorary Membership in the Materials Research Society of India, the Walston Chubb Award for Innovation, an Honorary Degree from Nanyang Technological Univ. Singapore, recognition as the Lee Kuan Yew Distinguished Visitor to Singapore, an Honorary Professorship from Hunan Univ. China, the ACS Award for Creative Invention, the Herman S. Bloch Award for Scientific Excellence in Industry, an Einstein Professorship of the Chinese Academy of Sciences, the Edward Mack Jr. Memorial Award, the $500,000 Lemelson-MIT Prize, the Havinga Medal, the Gustavus John Esselen Award, the Biomedical Eng. Society’s Distinguished Achievement Award, a DoD NSSEFF Award, the Pittsburgh Analytical Chemistry Award, the ACS Inorganic Nanoscience Award, the iCON Innovator of the Year Award, a NIH Director’s Pioneer Award, the Collegiate Inventors Award, an Honorary Doctorate Degree from Dickinson College, the Pennsylvania State Univ. Outstanding Science Alumni Award, the ACS Nobel Laureate Signature Award for Graduate Education in Chemistry, a Dickinson College Metzger-Conway Fellowship, the 2003 Raymond and Beverly Sackler Prize in the Physical Sciences, the Feynman Prize in Nanotechnology, the Leo Hendrick Baekeland Award, Crain’s Chicago Business “40 under 40 Award,” the Discover 2000 Award for Technological Innovation, I-Street Magazine’s Top 5 List for Leading Academics in Technology, the Materials Research Society Young Investigator Award, the ACS Award in Pure Chemistry, the PLU Fresenius Award, the Harvard University E. Bright Wilson Prize, the BF Goodrich Collegiate Inventors Award, the Camille Dreyfus Teacher-Scholar Award, the Alfred P. Sloan Foundation Award, the DuPont Young Professor Award, the NSF Young Investigator Award, the Naval Young Investigator Award, the Beckman Young Investigator Award, and the Camille and Henry Dreyfus Foundation New Faculty Award.</em></p><p><em>Mirkin served as a Member of the President’s Council of Advisors on Science &amp; Technology (Obama Administration) for eight years, and he is one of very few scientists to be elected to all three US National Academies (Medicine, Science, and Engineering), and in addition, he is a Member of the American Academy of Arts and Sciences, and a Fellow of the National Academy of Inventors, the American Chemical Society, the American Institute for Medical and Biological Engineering, the Materials Research Society, and others. Mirkin has served on the Editorial Advisory Boards of over 30 scholarly journals, including JACS, Acc. Chem. Res., Angew. Chem., Adv. Mater., Biomacromolecules, Macromolecular Bioscience, SENSORS, Encyclopedia of Nanoscience and Nanotechnology, Chem. Eur. J., Chemistry &amp; Biology, Nanotechnology Law &amp; Business, The Scientist, J. Mater. Chem., J. Cluster Sci., and Plasmonics. He is the founding editor of the journal Small, one of the premier international nanotechnology journals, and he has co-edited multiple bestselling books.</em></p><p><em>Mirkin holds a B.S. degree from Dickinson College (1986, elected into Phi Beta Kappa) and a Ph.D. degree in Chemistry from Penn. State Univ. (1989). He was an NSF Postdoctoral Fellow at MIT prior to becoming a professor at Northwestern Univ. in 1991.</em></p><h4>We sat down with Chad Mirkin to ask his viewpoints on everything from entrepreneurial lab culture, what he looks for in new research topics, to advice on building companies…</h4><h4>1</h4><h4>What advice would you give to founders working with University Tech Transfer looking to spinout out a company?</h4><blockquote>“Tech transfer is an extremely important part of our entrepreneurial ecosystem at the academic level. Establish a good working relationship with members of your tech transfer office early in your independent career and make sure you know how the process works.”</blockquote><h4>2</h4><h4>Can you describe your process for vetting new ideas to pursue in your lab?</h4><blockquote>“We go where the science takes us. We are not afraid to delve into new areas because we always operate from a foundation firmly rooted in the scientific method as a basic approach to doing good science. We want to pursue ideas that are scientifically new and innovative, fundamentally interesting, and that open new fields and have great societal benefit.”</blockquote><h4>3</h4><h4>How do you establish an effective entrepreneurial lab culture?</h4><blockquote>“In my university lab, my focus is not on entrepreneurship, it is on teaching. I try to make my group the best possible training ground for the next generation of thought-leaders in science and engineering. That being said, my students are listed as inventors on patents and have a stake in any IP that evolves out of their work.”</blockquote><h4>4</h4><h4>What advice would you give to professors trying to entrepreneurialize their labs?</h4><blockquote>“Professors should not be focused on entrepreneurializing their labs. However, if they are in the right mindset and if the work is appropriate, they can work to translate their discoveries through the proper channels in the tech transfer and business communities.”</blockquote><h4>5</h4><h4>Outside of academia, what is one seemingly random activity that helps make you a better researcher?</h4><blockquote>“I enjoy spending time with my family. They put things in perspective for me and help me recharge, so that I can bring the best version of myself to my lab and operate at a high level.”</blockquote><h4>6</h4><h4>How do you identify the point at which a scientific discovery is ripe for commercialization?</h4><blockquote>“In certain cases, the ground rules are already laid out. For example, when you have a nanomedicine that you are developing in the lab, you test it in in vitro then in cells then in animals on up to in humans. If the data continues to drive the case for commercialization along the translational trajectory, we continue to proceed.”</blockquote><h4>7</h4><h4>What advice can you give to academics raising their first round of venture funding?</h4><blockquote>“Believe in the technology you are selling, and leave your ego at the door. Be willing to handle rejection and criticism, don’t take it personally. The business world operates on a different set of rules than academic environments do.”</blockquote><h4>8</h4><h4>What advice would you give to business professionals looking to get in contact/help commercialize startups spinning out of academia?</h4><blockquote>“Reach out to the professors directly to make personal connections. Set up meetings to explore if your goals align.”</blockquote><h4>9</h4><h4>What advice would you give to professors in balancing founding a company and continuing to pursue academic research?</h4><blockquote>“It’s a big, but rewarding, job. Surround yourself with people that you trust and that are good decision-makers. Then, get out of their way and let them excel.”</blockquote><h4>10</h4><h4>What has been the most helpful piece of advice you received throughout your career as an academic entrepreneur?</h4><blockquote>“There are going to be huge highs and low lows in business. You have to be willing to ride out either case and keep a level-head.”</blockquote><p>📣 <strong>If you enjoyed this post please clap 👏 &amp; comment </strong>💬 <strong>to let us know</strong></p><p>❤️ Thanks <a href="https://medium.com/u/d4a12fd97637?source=post_page-----1b4f1f3e5213-----------------------------------"><strong>Andrew Yashar</strong></a> for your help in putting this together :)</p><h3>Join BIOS Community 🎉</h3><p>Become a member, continue the conversation, connect with like-minded Life Science innovators, access exclusive resources, &amp; invite-only events…</p><p><strong>Apply to Join — </strong><a href="https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform"><strong>Membership Application</strong></a></p><h3>For More Interesting Content 💭</h3><p>🧬 <strong>Podcast</strong> — <a href="https://open.spotify.com/show/2HmcPq9k8fYpn60F3hw6Ra?si=Qk9UeVGUSQajclaTYzN2uQ">Stream Full Episodes</a></p><p>🧪 <strong>YouTube </strong>— <a href="https://www.youtube.com/channel/UCWadRaYPrE1kE4t9LuCd28w">Watch Videos</a></p><p>🩺<strong> Twitter </strong>— <a href="https://twitter.com/bios_community">Explore Feed</a></p><p>🦠 <strong>LinkedIn</strong> — <a href="https://www.linkedin.com/company/bios-community">Read Posts</a></p><p><strong>Subscribe to BIOS Newsletter for special content: </strong><a href="https://www.bios.community/content"><strong>Click Here</strong></a><strong> 🔥</strong></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=db47fefa769d" width="1" height="1" alt=""><hr><p><a href="https://medium.com/bios-community/10-questions-w-chad-mirkin-professor-northwestern-db47fefa769d">10 Questions w/ Chad Mirkin — Professor @ Northwestern</a> was originally published in <a href="https://medium.com/bios-community">BIOS Community</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Founder Spotlight #49: Wyatt McDonnell @ Infinimmune]]></title>
            <link>https://medium.com/bios-community/founder-spotlight-49-wyatt-mcdonnell-infinimmune-a9808ed25e66?source=rss-183f327fce8c------2</link>
            <guid isPermaLink="false">https://medium.com/p/a9808ed25e66</guid>
            <category><![CDATA[entrepreneurship]]></category>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[founders-spotlight]]></category>
            <category><![CDATA[science]]></category>
            <dc:creator><![CDATA[BIOS]]></dc:creator>
            <pubDate>Tue, 28 Mar 2023 22:16:01 GMT</pubDate>
            <atom:updated>2023-03-28T22:16:01.676Z</atom:updated>
            <content:encoded><![CDATA[<p><a href="https://www.bios.community/"><strong><em>BIOS</em></strong></a><strong><em>: </em></strong><em>Nucleus of Life Science Innovation 🚀</em></p><h4>JOBS</h4><ul><li><strong><em>BIOS Talent: </em></strong><a href="https://medium.com/bios-community/bios-talent-worlds-first-techbio-job-board-weekly-newsletter-7d747d78dfaa"><em>Find Jobs @ Breakout TechBio Companies </em></a><em>— </em><a href="https://jobs.bios.community/companies"><strong><em>Search Jobs</em></strong></a><em> 🚀</em></li><li><strong><em>Post Jobs: </em></strong><em>Add Your Startup to BIOS Talent — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLScR_bLlCQ7Ie6bJ_HZ_dJ_LmuV3TsDEi-aNDC8N9GPz6psk1Q/viewform"><strong><em>Post Now</em></strong></a><strong><em> </em></strong><em>🎉</em></li><li><strong><em>Students:</em></strong><em> </em><a href="https://www.alix.vc/students"><em>Join Alix Ventures Fellowship</em></a><em> — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSckliaB67e-W2o9cmSbRNPLKrBBmtAx_S6CiFufc6QwHSCWSg/viewform"><strong><em>Join Now</em></strong></a><em> 🧬</em></li><li><strong><em>BIOS Contributor:</em></strong><em> </em><a href="https://medium.com/bios-community/write-for-bios-guest-contributor-aff9fbe6e1e"><em>Share Your Thought Leadership</em></a><em> — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSdGPtCdigoAu0ePKvsgcq08qPwRFWkKrHOjIQe7nCP5II_Xeg/viewform"><strong><em>Join Now</em></strong></a><em>🔬</em></li></ul><h4>CONTENT &amp; COMMUNITY</h4><ul><li><strong><em>BIOS Daily:</em></strong><em> Join 25K+ Subscribers Following TechBio — </em><a href="https://www.bios.community/content"><strong><em>Sign Up</em></strong></a><em> 🔥</em></li><li><strong><em>BIOS Insider: </em></strong><em>Premium TechBio Thought Leadership — </em><a href="https://bioscommunity.substack.com/"><strong><em>Sign Up</em></strong></a><strong><em> </em></strong><em>✨</em></li><li><strong><em>BIOS Commons: </em></strong><a href="https://medium.com/bios-community/introducing-bios-fostering-early-stage-healthcare-life-sciences-innovation-78c11dd57fff"><em>World’s Largest #TechBio Community</em></a><em> — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform"><strong><em>Join Now</em></strong></a><strong><em> </em></strong><em>🎉</em></li></ul><h4>INVEST</h4><ul><li><strong><em>BIOS Angels:</em></strong><em> </em><a href="https://medium.com/bios-community/introducing-bios-angels-worlds-1st-techbio-angel-syndicate-5faec24d8439"><em>1st TechBio Angel Investing Syndicate </em></a><em>— </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSe_0k-Ehi2uzTa_geqDm_B9kuRVWNyrvWSU7ch_5hqEKMoahg/viewform"><strong><em>Join Now</em></strong></a><strong><em> </em></strong><em>🌟</em></li><li><strong><em>Alix Limited: </em></strong><em>Invest in Breakout TechBio Startups — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSfqKG3fZOcXTtZTwKEk3wOvN0CyIIUBZkn-FFf5JhRHE1zW0Q/viewform"><strong><em>Learn More</em></strong></a><strong><em> </em></strong><em>🧠</em></li></ul><h4>By:</h4><p><a href="https://www.alix.vc/"><strong><em>Alix Ventures</em></strong></a><strong><em>: </em></strong><em>Supporting Early Stage Life Science Startups Engineering Biology to Drive Radical Advances in Human Health</em></p><p><strong><em>Calling All Innovators </em></strong><em>— </em><a href="/service/mailto:partners@alix.vc"><em>Click to Reach Out</em></a><em> 🚀</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*jZSLv2PCmvWwIDQXc-3iuw.png" /></figure><p><a href="https://www.infinimmune.com/"><strong><em>Infinimmune</em></strong></a><em> is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These truly human antibodies are designed to drug new targets with improved safety and efficacy. Infinimmune will deploy its holistic approach to build its own pipeline of drug candidates and partner with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications. To learn more, visit </em><a href="https://www.infinimmune.com/"><em>infinimmune.com</em></a><em> and engage with us on </em><a href="https://www.linkedin.com/company/infinimmune"><em>LinkedIn</em></a><em> and </em><a href="https://twitter.com/infinimmune"><em>Twitter</em></a><em>.</em></p><p><a href="https://www.linkedin.com/in/wyattmcdonnell/"><strong><em>Wyatt McDonnell</em></strong></a><strong><em> </em></strong><em>is Co-Founder, CEO, &amp; Chairman of the Board of Directors @ Infinimmune, a biotechnology company utilizing natural immunity to transform natural antibodies into safer and more effective drugs for complex diseases. Previously, Wyatt developed 10x Genomics’ first therapeutic antibodies and core immunology intellectual property behind three commercial products to interrogate the immune repertoire. He has co-authored 31 peer-reviewed papers in journals including Nature, Cell, and Nature Medicine, and 19 published patents in relation to immunobiology, genomics, and disease. He has been invited to speak at conferences including PEGS, the Keystone Symposia, the World Vaccine Congress, and PMWC.</em></p><h3>Personal Spark</h3><h4>What prompted you to pursue a career in Life Sciences? Was there a specific moment in time or influence you can remember?</h4><p>I grew up in a rural town in northern Michigan where there wasn’t a lot to do but there was an excellent public library, nature all around, and a good public school system. My folks didn’t really let us watch TV or movies, but would let us read almost anything we could find, went out of their way to take us to museums and made sure we went on every school field trip, and spent a lot of time encouraging us to think about and engage with anything that piqued curiosity. The first photo of me in a lab is from when I was 5 or 6 years old and a family friend showed me how to turn a copper penny silver by redox reactions — I remember that being absolutely magical.</p><p>Most of my early interest in science was closer to natural history — my mom and dad picked up a cheap used microscope and slide set of various tissues that I wore out. That microscope set was a good example of how I would obsess over a science/nature-related thing for a number of months and then land on a new interest. Unsurprisingly, I wound up collecting rocks, seashells, ladybugs (family Coccinellidae), butterflies, encyclopedias (fish, birds, mammals, dinosaurs), and most recently antique medical and immunology textbooks and correspondence.</p><p>It was easy to keep up my interests because I was lucky and had many excellent science and humanities teachers from elementary school through college. I also benefited from being able to do increasingly formal research from about 12 years old onwards — I started with calculating bullet velocities and comparing to manufacturer specifications in middle school, public health surveys in high school, and zapping drug-resistant <em>S. aureus</em> bacteria with blue light and heme precursors in college. I landed on immunology in grad school because it’s a fast-moving and complex field and because immunology is at the center of many of history’s most impactful drugs. Working in biotech is immensely satisfying because it’s difficult to get bored, the problems you solve require fun and brilliant interdisciplinary teams, and the end products you work on can create a different world for patients, providers, and scientists.</p><h4>How did you get your training to be able to build your company?</h4><p>I did 3 years of research in college and was able to take focused and deep coursework in virology, immunology, molecular biology, and cellular biology with small class sizes, journal clubs, and dedicated labs. I went to grad school thinking I was going to work on bacterial immunology, and fell in love with adaptive immunity instead. I was fortunate enough to be mentored by clinician-scientist Simon Mallal and his research teams at Vanderbilt University and the Institute for Immunology and Infectious Diseases at Murdoch University in Australia, and by Ivelin Georgiev, a computational biologist starting his professorial career out of a deep structural and computational antibody background at the NIH’s Vaccine Research Center. Along the way, I gained exposure to automated robotics, a few programming languages, a lot of molecular biology and human immunology, and a very healthy dose of reality (research is time-consuming, hard to do well, and mostly you need to listen and learn constantly). My PhD committee included basic and translational scientists and clinicians, who were very supportive of letting me wander through projects and help other groups with their research.</p><p>I got a ton of early exposure to single cell sequencing with the 10x Genomics Chromium platform, which was a fascinating and hackable piece of biotechnology, and my experience with that platform led to a job at 10x Genomics directly out of my PhD. I spent a few years at 10x working on their existing immune repertoire products and shipping a new one, BEAM, and gained exposure to business development, industry IP development, and how to model from scratch how you invest in building a new product. Learning how to think about and solve problems during my PhD and then putting those skills to work in industry is a common and useful combination of experience for myself and many others in industry.</p><h4>Can you tell us a little bit about your background &amp; career thus far? What were you doing before you started running a high potential venture backed startup?</h4><p>Before I started Infinimmune, I was working at 10x Genomics, where my role was interdisciplinary and involved doing core R&amp;D, inventing and protecting IP, providing one of many opinions on future business opportunities, and serving as a customer-facing expert and “internal consultant” on immunology-related opportunities. This kind of role is hard to find and you have to get lucky in finding a great company and managerial team who will enable and support you in your work, and this experience remains useful to me on a daily basis. It was also where I bumped into my future co-founders and gained a deep appreciation not just for the many types of expertise that are required to solve hard problems but also for how rare impactful life science tools companies are. At Infinimmune we decided from day one that we weren’t going to build and sell tools because we could have a bigger impact applying the incredible tools that already exist to meaningful problems instead of trying to sell yet another tool.</p><h4>Anything else you’d like to share about your life, academic trajectory, etc.?</h4><p>Several “early” life experiences continue to push me into working on problems that can reduce suffering. Our immediate and extended family has had experience with aggressive pediatric lymphoma, Huntington’s disease, rheumatoid arthritis, and comorbidities from chronic viral infections. Many people like me who have watched these events happen in their family, sat at deathbeds, and listened to patients end up being motivated to build better drugs or drugs that don’t yet exist. We traveled a lot when I was younger, which also drove home that there’s a lot of beauty all over the world and there’s also a lot of suffering that’s hard to appreciate without leaving the ZIP code you grew up in.</p><h3>Company Overview</h3><h4>Quite simply, what does your company do?</h4><p>Infinimmune is working on building safer, better antibody drugs for multiple diseases by developing drug candidates from safe and effective antibodies produced by the human immune system. The success and impact of antibody drugs in the past two decades have been impossible to ignore — conversely, the tools to directly screen and identify antibodies in human immune systems are extremely new and human antibody responses are poorly understood. Many acute and chronic diseases have immune-mediated components, but immunotherapies are not available for most of these diseases. In a world where antibodies and biologics are taking over and effectively treating many diseases, we build antibodies which nature has already validated for their safety and efficacy in the human body.</p><h4>Now in more depth, what are the specifics of what your company does?</h4><p>Infinimmune screens the human immune system for antibodies that are impossible to identify from any other process, by sequencing antibodies of single B cells, engineering these antibodies to help large populations of patients, and identifying novel antibody biology and targets.</p><h4>How did you become motivated to tackle this particular problem?</h4><p>Infinimmune is working on building safer, better antibody drugs for multiple diseases by developing drug candidates from safe and effective antibodies produced by the human immune system. The success and impact of antibody drugs in the past two decades have been impossible to ignore — conversely, the tools to directly screen and identify antibodies in human immune systems are extremely new and human antibody responses are poorly understood. Many acute and chronic diseases have immune-mediated components, but immunotherapies are not available for most of these diseases. In a world where antibodies and biologics are taking over and effectively treating many diseases, we build antibodies which nature has already validated for their safety and efficacy in the human body.</p><h4>Why does your solution matter for the world when you get it right?</h4><p>When we get this right, we will be able to deliver antibody drugs for humans, from humans — this will mean fewer side effects, more affordable medicines because of increased potency, and an improved understanding of how the human immune system deploys autoimmunity to protect us.</p><h3>Genesis</h3><h4>Tell us about the founding of your company — how did everything come together?</h4><p>All of Infinimmune’s founders had decided they wanted to move on from tackling life science product commercialization to tackling new problems in human health at various times between 2021 and 2022. I sat down to grab a beer with our co-founders in July 2022, sketched out a few ideas, incorporated, started fundraising and doing proof-of-concept work, which culminated in a $12M seed round in the fall of 2022. The tools that are best positioned to understand and learn about the adaptive immune system have been underadopted and underapplied, and our founding team couldn’t stop thinking about the prospect of building better drugs while learning about the actual targets of the human adaptive immune system.</p><h4>How did you meet your co-founders?</h4><p>Infinimmune’s co-founders all worked at 10x Genomics previously, mostly indirectly and in very different roles, and depending on which pair of founders you pick have known each other for 2–7 years. Funnily enough, when I was hired by 10x, David Jaffe, one of our computational co-founders, was one of my interviewers. I ended up sending him a note after the interview with some more thoughts/reading material in response to a very interesting question he asked me. Unsurprisingly, David and I ended up working closely together for most of my time at 10x across multiple projects.</p><h4>Was there a specific moment when you knew you should pursue this business idea? If so, what was it?</h4><p>We’d all seen a series of small but meaningful step changes in biotechnology, some of which we’d contributed to at 10x Genomics, set against a backdrop of the world finally paying attention to antibodies full-time during the COVID-19 pandemic, and validated by several direct-from-human drugs reaching the clinic and even FDA approval. Several pieces of data analysis that we completed led us to realize that we could build some core technical functionalities that were unlikely to be built by or even tractable for life science tools companies. A <a href="https://www.nature.com/articles/s41586-022-05371-z">recent paper in Nature</a> from two of Infinimmune’s co-founders about a new property of antibodies light chain coherence strengthened our resolve that screening human immune repertoires in antigen-specific and antigen-agnostic fashion wasn’t a fool’s errand, and our investors shared our enthusiasm!</p><p>There were two cool early moments when we had a pretty good idea that things were going to move forward. The first was when what was supposed to be a 1-hour-walk-and-talk with Josh Elkington (one of our earliest supporters) turned into a 4-hour-hike-most-of-Berkeley. The second was when my first meeting with Jory Bell and Ben Kim from Playground turned from a half hour meet-and-greet into a 3-hour whiteboard session.</p><h4>Timing is everything — how did you know the timing was right?</h4><p>Each of us had watched some incredible tools start to change the face of biological research and clinical medicine — DNA sequencing, single cell sequencing, biomanufacturing, and a long-running streak of blockbuster antibody drugs. We also watched many great biotech companies get beat up in the public market and figured that now was as good a time as any to start a new company, recruit incredible talent, and take advantage of technological innovations that still haven’t deeply penetrated life sciences.</p><h3>Accomplishments</h3><h4>What are some of the notable milestones your company has achieved thus far?</h4><ul><li>We recently closed a $12 million series seed round, led by Playground Global with participation from Pear VC, Civilization Ventures, Axial VC, and angel investors Ron Alfa, Paul Conley, and Joshua Meier.</li><li>It took just 3 months for Infinimmune to close its seed round beginning in mid-July 2022 when we incorporated.</li><li>We’ve hired our first two team members and are hiring more talented folks to work end-to-end on new therapeutic antibodies (including BD)! Please get in touch via <a href="/service/mailto:careers@infinimmune.com">careers@infinimmune.com</a> or <a href="/service/mailto:founders@infinimmune.com">founders@infinimmune.com</a> if you’d like to bring your skills to bear on the problems we’re solving!</li></ul><h4>What are some of the biggest hurdles ahead? How do these create points of value inflection?</h4><p>Infinimmune’s long-term strategic hurdles fall into two categories: hurdles that affect all companies building antibody drugs, and asset-specific hurdles related to the biology of antibody drugs built at Infinimmune. Fortunately for us we get to benefit from decades of excellent legacy work in assessing, protecting, and testing antibody drug candidates. We spend more time thinking about how antibodies from humans could behave in unexpected ways in preferred models of specific diseases, require additional engineering for manufacture in industry-standard CHO cell lines, and how lead optimization and selection for human antibodies might differ from antibody candidates derived from other discovery workflows. In the meantime, we’re also focused on meeting strategic milestones in advance of future fundraising.</p><h3>Pay It Forward</h3><h4>Throughout the journey, what have been some of your biggest takeaways thus far? What advice/words of wisdom would you share from your story for other founders?</h4><p>For me personally, having multiple co-founders that I trust and respect deeply at Infinimmune has been unbelievably empowering. I have deep respect for the insanity and vision found in solo founders. Being able to start a company with a team whose advice and feedback you can listen to has made all the difference for us — and that applies to our investors too! You want to build a team within and around your company who you can listen to when they have feedback to share.</p><p>Beyond finding and listening to people you can trust, learning how to start, fund, and operate a company for me has boiled down to two sources: speaking to other founders, and reading-thinking-doing-repeating. There’s a ton of advice on how to do this that you’ll be able to find, though you may not be able to take advantage of all of it, and some of it you may not want to take at all. You’ll learn more about how to start a company by getting going and starting than you will by reading about it, and that’s why you should try to connect “doing/testing” to advice you read. Experiments don’t just happen in the lab!</p><p>Lastly, patience and focus are required. It will take you time for you to figure out what you actually want to do, what you will do, and how you’ll bring new team members and investors or funders alongside to make it happen. There will be a million things you can do with your time. Focus on getting just one high priority thing done at a time, find a mental model or tool that works for you such as the urgency-importance matrix, and stick to it. Nobody will identify your critical path for you, so it’ll be on you and your team to figure out the order of events and what does and doesn’t matter. Speaking to people who have done this before will help you find strategies that you can try out and will remind you that this process is as exhilarating as it is exhausting!</p><h4>What are some of the must-haves for an early stage Life Sciences startup in your eyes? (Key critical components like team, academic papers, industry know-how, etc.)</h4><p>I think the exact critical components are highly dependent on what you’re trying to do, what your background as a founder is, and how you want to grow the company. If you’re trying to build a tools company, you’re going to need advice and hands-on help with engineering, productization, commercialization, and builders for software/hardware/kits/etc. If your company will be built around a drug for a specific disease, you’ll need to focus on how you’re going to find candidates (or why your candidate is better than what’s out there), get detailed early-on about clinical trial details, bring in experts in the indication you’re targeting, and focus on finding investors who are comfortable with high-risk-high-reward asset investing. If you’re an academic spinning out a company, you’ll want to read resources like 50 Years’ Spinout Playbook and focus on getting your tech transfer knocked out and deciding who will help you operate your company and if you’re going to also come out of academia to run your company. In almost all cases, you will be well-served by finding people who have worked in industry for a number of years because the pace of work in industry and in startups is much different than academia, and if you’re coming from industry, you don’t want to drop that pace. Above all else, hire to cover your blind spots and spend time figuring out what you don’t know and are missing — assuming that you’ll be able to single-handedly learn everything you need to do to succeed is a huge mistake.</p><h4>What are some of the traits that make a good founder? What type of risk profile/archetype does someone need to have to be a founder in your opinion?</h4><p>As a first-time founder, I don’t think I’m well-qualified to answer this question convincingly — I can probably speak more accurately to “what types of traits do you see in founders” than “what distinguishes great founders from not-as-great founders”. My intuition is that folks who are very risk-averse will be very uncomfortable starting a company or even joining a new or early startup. You’ll need to be comfortable being flexible, dropping and picking up ideas rapidly, and you’ll need to be good at starting and continuing conversations when somebody says “no, not now”, “I don’t understand”, “that doesn’t make sense to me”, “can you say more?”. If explaining things without getting frustrated doesn’t come easily to you and you’re still hellbent on starting a company, find a co-founder whose strength fills that gap. I would assume that some level of passionate, deeply held belief or vision that your work will lead to a different and better world is also necessary, and an ability to articulate that to many different people. My last assumption is that great founders are capable of “executing” (which is an overused and abused word in this space) rapidly and not letting things fall through the cracks. That last bit probably requires some degree of obsessive or compulsive tendency, or maybe none at all and I’m just projecting. Ashamed to say I don’t remember where I read this, but another combination of traits that might make sense is “not hesitant to disagree but also open-minded” (I think the original version was “disagreeable but open-minded”).</p><h4>For folks coming out of academia, what advice would you share?</h4><p>Get connected with other founders and folks with industry experience immediately. In my opinion you should do this before speaking with your tech transfer office so that you’re getting high-quality external advice from operators and not university employees who aren’t really invested in your short- or long-term vision.</p><h4>Not everyone knows everything. Often founders have to learn either the science or the business side better. What advice would you give for someone picking up a new skill set such as this?</h4><p>Try to figure out if you’re going to be any good at it early. If you’re not making rapid progress and improving, quit, and find help! If it’s going well, do an inventory of which skills you’re going to end up failing to maintain, and make sure you’re finding help to cover the things that you’ll do less of if this becomes a focus area for you.</p><h4>Can you demystify the process of what it takes to raise VC funding? What were the highlights &amp; lowlights? Any advice or words of wisdom for future founders?</h4><p>Raising VC funding is probably a pretty unique experience both for individuals and specific companies that they start. You need to start getting to know people months in advance of “running the process” — investors need to learn about you, what motivates you, how you interact with people, and see how your vision of your company changes over time. We took on no convertible debt or convertible notes, self-funded (no friends or family) while doing proof of concept, and made our first fundraise a priced round, which helped us select some extremely helpful and high-quality investors. Some of our first conversations were great practice even though we weren’t a fit for some of those investors — and that’s totally okay, very common for all companies, and worth doing! We were able to use the time in the summer to get work done prior to Labor Day, and then ran our fundraising process immediately after, which also worked well for us. Along the way we had a great back-and-forth with our investors throughout the process that improved the quality of our thinking about Infinimmune and the quality of our fundraise, so I’d also encourage new founders to embrace the collaborative aspect of fundraising as much if not more than the adversarial aspect. Don’t underestimate the power of a few smart and well-connected angel investors or “one-person shops” either.</p><h4>What advice for managing and hiring a great team can you share?</h4><p>Management styles don’t necessarily generalize — I’d recommend taking some time to reflect on what you’ve seen work well for leaders you’ve worked for and admire. We ask prospective employees at Infinimmune what some of their favorite and least favorite attributes of their past managers and mentors are, for starters. We also ask them what would have happened if they were to leave Infinimmune in just 1–2 years — this gives candidates an opportunity to talk about why they’re looking for new employment if they’re comfortable talking about it, but also some context for how they want to grow and what they’re looking for in leaders. Asking people you admire for concrete examples of managers and leaders they admire and have worked for is also helpful. Some things are very common across disciplines (“they delegate well”, “they listen well and then take action”) and others are very specific (“in addition to being a respectable human this person also has technical and hands-on experience that makes them qualified to run their team and identify other brilliant people to hire”).</p><p>Everybody will tell you to be careful with hiring, and they’re right! We prefer hiring slowly and deliberately so that we bring somebody on when there’s not just a specific role for them but a long-term career. Specific things we have found useful at Infinimmune include phone/video screens with &gt;1 person, “small group” sessions during interviews, and using a non-standard set of largely behavioral questions. If this is your first time hiring, you can learn how to do this by reading (I personally recommend <em>Talent</em> by Tyler Cowen and Daniel Gross, taken with several grains of salt), working with a recruiter so that you can see a volume of resumes and understand how people present themselves (though you may not end up using a recruiter at all), and most importantly taking some time to think about whether questions you’re planning to ask in an interview will actually teach you something about the person you’re interviewing and provide them with an opportunity to shine.</p><p>📣 <strong>If you enjoyed this post please clap 👏 &amp; comment </strong>💬 <strong>to let us know</strong></p><p><em>Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement or recommendation by Alix Ventures, BIOS Community, or its affiliates. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by Alix Ventures employees are those of the employees and do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, and content sponsors.</em></p><h3>Join BIOS Community 🎉</h3><p>Become a member, continue the conversation, connect with like-minded Life Science innovators, access exclusive resources, &amp; invite-only events…</p><p><strong>Apply to Join — </strong><a href="https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform"><strong>Membership Application</strong></a></p><h3>For More Interesting Content 💭</h3><p>🧬 <strong>Podcast</strong> — <a href="https://open.spotify.com/show/2HmcPq9k8fYpn60F3hw6Ra?si=Qk9UeVGUSQajclaTYzN2uQ">Stream Full Episodes</a></p><p>🧪 <strong>YouTube </strong>— <a href="https://www.youtube.com/channel/UCWadRaYPrE1kE4t9LuCd28w">Watch Videos</a></p><p>🩺<strong> Twitter </strong>— <a href="https://twitter.com/bios_community">Explore Feed</a></p><p>🦠 <strong>LinkedIn</strong> — <a href="https://www.linkedin.com/company/bios-community">Read Posts</a></p><h4>Subscribe to BIOS Newsletter for special content: <a href="https://www.bios.community/content">Click Here</a> 🔥</h4><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a9808ed25e66" width="1" height="1" alt=""><hr><p><a href="https://medium.com/bios-community/founder-spotlight-49-wyatt-mcdonnell-infinimmune-a9808ed25e66">Founder Spotlight #49: Wyatt McDonnell @ Infinimmune</a> was originally published in <a href="https://medium.com/bios-community">BIOS Community</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Founder Spotlight #48: Richard Novak @ Unravel Biosciences]]></title>
            <link>https://medium.com/bios-community/founder-spotlight-48-richard-novak-unravel-biosciences-e7ebcf654d53?source=rss-183f327fce8c------2</link>
            <guid isPermaLink="false">https://medium.com/p/e7ebcf654d53</guid>
            <category><![CDATA[entrepreneurship]]></category>
            <category><![CDATA[science]]></category>
            <category><![CDATA[founders-spotlight]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[venture-capital]]></category>
            <dc:creator><![CDATA[BIOS]]></dc:creator>
            <pubDate>Tue, 28 Mar 2023 22:15:18 GMT</pubDate>
            <atom:updated>2023-04-07T14:19:36.961Z</atom:updated>
            <content:encoded><![CDATA[<p><a href="https://www.bios.community/"><strong><em>BIOS</em></strong></a><strong><em>: </em></strong><em>Nucleus of Life Science Innovation 🚀</em></p><h4>JOBS</h4><ul><li><strong><em>BIOS Talent: </em></strong><a href="https://medium.com/bios-community/bios-talent-worlds-first-techbio-job-board-weekly-newsletter-7d747d78dfaa"><em>Find Jobs @ Breakout TechBio Companies </em></a><em>— </em><a href="https://jobs.bios.community/companies"><strong><em>Search Jobs</em></strong></a><em> 🚀</em></li><li><strong><em>Post Jobs: </em></strong><em>Add Your Startup to BIOS Talent — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLScR_bLlCQ7Ie6bJ_HZ_dJ_LmuV3TsDEi-aNDC8N9GPz6psk1Q/viewform"><strong><em>Post Now</em></strong></a><strong><em> </em></strong><em>🎉</em></li><li><strong><em>Students:</em></strong><em> </em><a href="https://www.alix.vc/students"><em>Join Alix Ventures Fellowship</em></a><em> — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSckliaB67e-W2o9cmSbRNPLKrBBmtAx_S6CiFufc6QwHSCWSg/viewform"><strong><em>Join Now</em></strong></a><em> 🧬</em></li><li><strong><em>BIOS Contributor:</em></strong><em> </em><a href="https://medium.com/bios-community/write-for-bios-guest-contributor-aff9fbe6e1e"><em>Share Your Thought Leadership</em></a><em> — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSdGPtCdigoAu0ePKvsgcq08qPwRFWkKrHOjIQe7nCP5II_Xeg/viewform"><strong><em>Join Now</em></strong></a><em>🔬</em></li></ul><h4>CONTENT &amp; COMMUNITY</h4><ul><li><strong><em>BIOS Daily:</em></strong><em> Join 25K+ Subscribers Following TechBio — </em><a href="https://www.bios.community/content"><strong><em>Sign Up</em></strong></a><em> 🔥</em></li><li><strong><em>BIOS Insider: </em></strong><em>Premium TechBio Thought Leadership — </em><a href="https://bioscommunity.substack.com/"><strong><em>Sign Up</em></strong></a><strong><em> </em></strong><em>✨</em></li><li><strong><em>BIOS Commons: </em></strong><a href="https://medium.com/bios-community/introducing-bios-fostering-early-stage-healthcare-life-sciences-innovation-78c11dd57fff"><em>World’s Largest #TechBio Community</em></a><em> — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform"><strong><em>Join Now</em></strong></a><strong><em> </em></strong><em>🎉</em></li></ul><h4>INVEST</h4><ul><li><strong><em>BIOS Angels:</em></strong><em> </em><a href="https://medium.com/bios-community/introducing-bios-angels-worlds-1st-techbio-angel-syndicate-5faec24d8439"><em>1st TechBio Angel Investing Syndicate </em></a><em>— </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSe_0k-Ehi2uzTa_geqDm_B9kuRVWNyrvWSU7ch_5hqEKMoahg/viewform"><strong><em>Join Now</em></strong></a><strong><em> </em></strong><em>🌟</em></li><li><strong><em>Alix Limited: </em></strong><em>Invest in Breakout TechBio Startups — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSfqKG3fZOcXTtZTwKEk3wOvN0CyIIUBZkn-FFf5JhRHE1zW0Q/viewform"><strong><em>Learn More</em></strong></a><strong><em> </em></strong><em>🧠</em></li></ul><h3>By:</h3><p><a href="https://www.alix.vc/"><strong><em>Alix Ventures</em></strong></a><strong><em>: </em></strong><em>Supporting Early Stage Life Science Startups Engineering Biology to Drive Radical Advances in Human Health</em></p><p><strong><em>Calling All Innovators </em></strong><em>— </em><a href="/service/mailto:partners@alix.vc"><em>Click to Reach Out</em></a><em> 🚀</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*5NFcCpATY1ywywRBDi46ww.png" /></figure><p><a href="https://www.unravel.bio/"><strong><em>Unravel Biosciences</em></strong></a><strong><em> </em></strong><em>is a personalized therapeutics company that redefines diseases through RNA network analysis to seamlessly bridge target discovery with clinical efficacy of new drugs. Unravel leverages its proprietary BioNAV™ platform combining target and drug discovery, preclinical screening and patient stratification to find treatments for complex diseases impacting the whole body. Unravel’s platform discovered RVL001, a proprietary formulation targeting Rett Syndrome that will enter the clinic this year, and RVL002, a new small molecule with applications in CNS and metabolic diseases.</em></p><p><a href="https://www.linkedin.com/in/richardnovak/"><strong><em>Richard Novak</em></strong></a><strong><em> </em></strong><em>is a bioengineer and entrepreneur dedicated to solving unanswerable questions through technology innovation. Prior to Unravel Bio, he was a Lead Engineer at the Wyss Institute for Biologically Inspired Engineering at Harvard University where he managed fast-paced programs in drug discovery, advanced disease models, human Organ Chips, and integrated automation and sensor systems. He has over 15 years of experience in microfluidic system development and applications in the therapeutic space. He is a founder and president of the nonprofit </em><a href="https://www.futurescientist.org/"><em>Future Scientist</em></a><em> and a founder and director of the sample collection platform company </em><a href="https://rhinostics.com/"><em>Rhinostics Inc.</em></a><em> He received a BS in biology from Emory University and a PhD in Bioengineering from UC Berkeley.</em></p><h3>Personal Spark</h3><h4>What prompted you to pursue a career in Life Sciences? Was there a specific moment in time or influence you can remember?</h4><p>In my early childhood in the Czech Republic, my family spent most of our free time outside, picking berries and mushrooms in forests, gardening, and hiking. This continued after immigrating to the US, and I grew to love nature, and from there, biology. In high school, my father guided me to develop my own research studying turtle migration using genetic sequencing, and from there, I was hooked on a life science career trajectory. I gravitated to work specifically in advancing therapeutics after spending several months working in a remote corner of the Amazon rainforest and seeing the massive impact of parasitic infections and other under-resourced diseases, where rapid and efficient therapeutic interventions could have profound benefits.</p><h4>How did you get your training to be able to build your company?</h4><p>My initial response to the need for rapid interventions was to found Future Scientist with my PhD program colleagues. We felt that science and engineering education would enable communities to sustainably address challenges using locally available resources and have the most immediate impact on health. In the process, I was thrown into building a non-profit startup with all that company building entails: fundraising, team building, logistics (in this case bringing US students to Latin America through educational programs we designed), marketing, legal and accounting, and delivering a clear benefit to our stakeholders (communities and program participants). I am grateful for all the mentors and supporters who took us under their wings and provided guidance and reality checks we so badly needed to build a good company. This experience has stuck with me, not benefiting Unravel but also clearly demonstrating to me the value of mentorship and generosity with time.</p><p>I also gained a great deal of insight from NSF’s iCorps program on product-market fit, Creative Destruction Labs mentorship program, and multiple business competitions at UC Berkeley run through the Haas Business school. They provided exposure to a side of technology translation not easily achieved in a lab.</p><h4>Can you tell us a little bit about your background &amp; career thus far? What were you doing before you started running a high potential venture backed startup?</h4><p>I was a member of the Advanced Technology Team at the Wyss Institute at Harvard University, which is effectively a playground for scientists. I joined the Wyss because of the incredibly wonderful opportunity to lead teams on high risk high reward therapeutics and diagnostics programs with the specific mandate to identify translation and commercialization paths and mature technologies for outlicensing. As an engineer, I focused on the technology platforms, from Organ Chips that spun out into Emulate Bio to computational and screening platforms that led to Unravel and other companies. During the COVID pandemic, I, along with many others, was drafted into supporting the many hospitals around the Wyss Institute that were running into supply chain issues and specifically swabs shortages. Together with the incredible team at the Wyss, we developed a 3D printed swab that was tested in 3 days from first design, in a month an injection molded design was in volunteers, and another month after that was available as a sterile product at a million unit scale. I partnered with Michael Springer, a Harvard professor building Harvard’s diagnostic lab for regular testing, and together we developed a highly automatable swab that enabled his lab to run tens of thousands of SARS-CoV-2 tests per week with only a handful of staff. We spun that out into Rhinostics, which took the concept and has applied it to blood and genomics testing. All of these highly translational experiences with rapid impact only reinforced my desire to continue this trajectory within Unravel.</p><h4>Anything else you’d like to share about your life, academic trajectory, etc.?</h4><p>In high school and college, I was that annoying kid asking questions that couldn’t be answered with existing tools. So I became a tool builder, from custom genomics tests for turtles to a portable water filtration system to study parasites in streams. It took me an embarrassingly long time to realize that I approached everything through the lens of an engineer. Once I did, I embraced it fully, heading off to UC Berkeley for my PhD in Bioengineering and developing single cell microfluidic platforms at a time when we had to convince journal reviewers of the power of Poisson statistics and the value of single cell analysis. There I became enamored with rapid prototyping. I saw its immense value in reducing an initially intractable engineering problem into manageable components that could be efficiently solved. I applied this to Future Scientist’s curriculum, building on IDEO’s Human Centered Design principles that embody rapid yet systematic prototyping for humans, not hardware. I saw the impact of quickly testing multiple potential solutions in a matter of days with materials on hand to ensure that a final product would truly meet the needs of the end-users. I came with this perspective to the Wyss Institute, where our one and only command was to make an impact on the world by taking technologies out of the lab. Which technologies are best? For which problems? How fast can we do it? I realize that these were all questions suited to a rapid prototyping approach so embedded in engineering disciplines. At the Wyss, we built a prototype water purification system that heavily relied on a $3 bucket from Amazon and shipped it to partners in Panama to road-test it with potential end-users in remote villages. We did this even before we had the pathogen-killing technology fully functional so that we could get feedback on the envisioned solution and use that to refine the technology as early in development as possible.</p><p>My team and I took the same approach developing new swab designs in the earliest days of the COVID pandemic, bringing 3D printers home for the shutdown and handing off samples in COSTCO parking lots to not lose out on the value of rapid prototyping. The shared uncertainty around the pandemic enhanced collaboration, and prototyping surprisingly became easier as the rapid progress across all areas (devices, diagnostics, therapies, prevention) became impossible to ignore. I’ve now extended this rapid prototyping approach to therapeutics development.</p><h3>Company Overview</h3><h4>What problem is your company solving?</h4><p>Neurological disorders have been among the most challenging diseases to treat because drug candidates end up being in patients despite the most thorough preclinical target validation. Basically, the drug targets are wrong. In multiple clinical trials year after year we see a target being successfully engaged by a drug, sometimes changing a biomarker readout, all the while not bringing a therapeutic effect to the patients. On the other end of the spectrum, we have drugs, such as some oncology drugs, that do provide a meaningful benefit to patients but not through the targets they were originally developed for. We set out to build therapeutics programs that provide efficacy first without requiring an initial commitment to a drug target.</p><h4>How did you become motivated to tackle this particular problem?</h4><p>We were working on a DARPA program with Don Ingber to enable a patient to ignore or tolerate an infection such as sepsis and enable treatment in the field, as opposed to treating infections directly with antibiotics. As our drug candidates became quite effective, we started asking questions about how this could impact cognitive function once the acute phase of infection was addressed. It became apparent that these questions were difficult to answer, so we collaborated with Michael Levin at Tufts and the Wyss Institute, who spent a couple decades developing technologies to do just that. We soon saw the bigger opportunity of screening for cognitive and behavioral therapeutic effects in addressing diseases of the central nervous system, which are among the top most debilitating and unaddressed indications globally and with few tailored resources to tackle them.</p><p>It was here that I saw the opportunity to bring the iterative design-build-test prototyping cycle of engineering into drug development. While drug repurposing has long been the mainstay of fast drug development with many success stories, the process has largely been a brute-force approach with limited new drug potential. I wanted to take Unravel beyond repurposing concepts and focus on entirely new mechanisms without brute-force screening or being limited to existing knowledge (let’s face it, we are only scratching the surface of biology!). Most importantly, seeing the massive failure of translating preclinical results to patients, my co-founder Frederic Vigneault and I aimed for a fast-track path to the clinic, using existing drugs to prove out novel targets. This runs counter to a widely held myth that each drug has one or few drug targets one can look up in a database. In reality some drugs engage hundreds of proteins and other molecules in tissues in unique ways, and these potential targets are all interconnected. We realized that these existing drugs are the key to rapidly prototyping new targets in patients as a first step in developing new, effective therapies.</p><p>As a result, at Unravel we are asking the most important, end-user- facing question first: does the drug help the patient? By making that concept the north star of our company and building out a suite of cutting edge discovery tools and innovative clinical trial designs that let us quickly test a drug target in actual patients, we are testing the idea that biotechs can be accelerated through rapid prototyping.</p><h4>Quite simply, what does your company do?</h4><p>Unravel is at its simplest a precision medicine platform using patient transcriptome data to redefine disease states to accelerate drug discovery and test predictions in record time in patients. Unravel discovers new, often hidden targets for neurological disorders and immediately asks “will this help actual patients?” by quickly and inexpensively testing existing drugs in custom animal models and clinical trials. In parallel, we develop highly effective new therapeutics for the validated drug targets.</p><h4>Now in more depth, what are the specifics of what your company does?</h4><p>Unravel leverages its proprietary BioNAV™ platform for treating complex neurological diseases impacting the whole body where traditional target-driven drug programs have often failed, combining AI drug discovery, patient stratification, rapid preclinical screening, and efficient N-of-1 clinical trials to discover effective treatments. Unlike other personalized medicine approaches, Unravel uses RNA network signatures sensitive to dynamic changes in patients to simultaneously discover personalized treatments while stratifying other patients into therapeutic response groups to rapidly scale clinical and commercial impact regardless of the root cause.</p><p>Unravel’s target-agnostic approach has resulted in the identification of an entirely new drug target for treating Rett syndrome. The target and discovery platform are being clinically de-risked using RVL001, a promising proprietary formulation of an existing drug, in N-of-1 trials to assess individual patient response through frequent RNA sequencing. Unravel has already developed a new lead small molecule, RVL002, that safely and efficiently treats Rett syndrome preclinically through the discovered drug target with potential applications in other CNS and metabolic diseases. Other target and therapeutics discovery programs include the neurodegenerative disorder X-linked dystonia Parkinsonism, Okur-Chung Neurodevelopmental Syndrome, and bipolar disorder.</p><h4>Why does your solution matter for the world when you get it right?</h4><p>Imagine precisely and effectively treating patients based on their current disease states, not clinical symptoms or unclear genomic data, and without forcing a long and often inconclusive diagnostic odyssey. Imagine if you could quickly prototype a treatment in patients to help them while answering the most critical drug development questions first. This is what Unravel will achieve for the 10% of the world’s population with one of 15,000 rare diseases.</p><h3>Genesis</h3><h4>Tell us about the founding of your company — how did everything come together?</h4><p>My co-founder Frederic Vigneault and I started collaborating on an internal program at the Wyss Institute that for the first time combined multiple discovery technologies into a single program aimed at developing a treatment for Rett syndrome. We had been using Xenopus laevis tadpoles as a model organism of infection, and the tadpoles have well-developed brains with complex behaviors that could be suitable for screening neurodevelopmental disorder therapies. I asked Frederic, with his extensive experience in CRISPR development with George Church, if he could CRISPR engineer tadpoles to disrupt the MeCP2 gene that is known to cause Rett. His response was “yes of course, but why tadpoles if mice are already inaccurate models?” Long story short (and many attempts to try to make the tadpole models fail), we saw a beautifully synergistic platform taking shape. Tadpole engineering allowed us to easily generate entirely new and robust disease models in a couple weeks, computational predictions of candidate drugs and targets were rapidly translating into stunning results even in mouse models, and talking with clinicians made it clear that we may have a revolutionary solution for tackling neurological disorders not just for Rett but as a rapid prototyping approach suitable for any number of indications. What was to become the Unravel platform was extremely effective in uncovering specific COVID repurposing therapies that ended up having significant clinical impact based on electronic health records (another great form of rapid prototyping!). In parallel, we used the platform to develop artificial hibernation inducers for limb and organ preservation, exceeding DARPA 5-year milestones in just 2 years. All of those successes made it clear that our platform works, and Rett syndrome is the way to prove out our approach.</p><h3>Accomplishments</h3><h4>What are some of the notable milestones your company has achieved thus far?</h4><p>We raised a pre-seed round in 2021 to get the company operational. Of course the biotech market tanked soon thereafter, but we were able to hire a top team of scientist and computational experts, discover a new drug target for Rett, new pathways for several other indications, get to pre-IND in the US by bringing in Neal Muni as our Chief Medical Officer, discover and patent RVL002, a new molecule to treat Rett syndrome, and establish several partnerships and obtain grants.</p><h4>What are some of the biggest hurdles ahead? How do these create points of value inflection?</h4><p>Our key path is to show in a proof of concept clinical study how our platform can lead to new drug targets that actually are therapeutically effective. We are working with TMA Precision health, a CRO partner, on a clinical trial in Colombia to accomplish this while we continue to develop the high value new drug candidate. This single step will clinically validate our computational platform and rapid prototyping approach for further partnering while de-risking the drug target and new molecule to show how Unravel generates value directly through therapeutic assets.</p><h3>Pay It Forward</h3><h4>Throughout the journey, what have been some of your biggest takeaways thus far? What advice/words of wisdom would you share from your story for other founders?</h4><ul><li>Get used to hearing “no” more than you ever have! The corollary of that is to learn how to benefit and learn from those responses.</li><li>Surround yourself with people who want to find ways to achieve success. It’s too easy to come up with reasons for why something won’t work, and it rarely adds value. Instead, look for optimists who will chip in to make goals a reality or quickly find ways to pivot and keep moving forward.</li><li>Don’t get irrationally optimistic and attached to your preferred path. Be realistic about what works and what doesn’t and pivot as soon as you know you’re not making headway. This is where surrounding yourself with seasoned mentors is key in telling the difference between optimism and idealism.</li></ul><h4>What are some of the must-haves for an early stage Life Sciences startup in your eyes? (Key critical components like team, academic papers, industry know-how, etc.)</h4><p>Network, network, network. This builds a team and customers/partners, bridges any expertise gaps, and enables you to bounce ideas off of more neutral (or, ideally, critical) parties.</p><h4>For folks coming out of academia, what advice would you share?</h4><p>While individual academic labs can be quite distinct, from basic research focused to highly translational and entrepreneurial, none of them fully prepare an aspiring entrepreneur. However, there are many wonderful mentoring and accelerator programs that can provide a strong foundation, from NSF’s iCorps program, to Nucleate, to university-specific programs that are often partnered with business schools. YC, Petri, and other accelerators may be helpful once a startup kicks off.</p><h4>Not everyone knows everything. Often founders have to learn either the science or the business side better. What advice would you give for someone picking up a new skill set such as this?</h4><p>Do your best but don’t try to pick up all the skills yourself! Balance rapid uptake of what is a firehose of information and need for new skills with targeted expert support to fill the gaps. Much has been said about finding a great co-founder and legal counsel; on top of that, bring in accounting, marketing, regulatory, or technical expertise through contractors and vendors. A full time hire may not make sense early on, but at the same time one cannot afford to make mistakes in critical company-building steps. Also, I absolutely recommend bringing in interns, especially co-op students who work full time for many months. With the right support, everyone has marketable skills as well as a unique perspective that can helpfully challenge established assumptions, and motivated interns can be very cost-effective while providing specific value to startups.</p><h4>What advice for managing and hiring a great team can you share?</h4><ul><li>You spend a lot of time hiring great people to work on a project they are excited about. So let them! Get out of their way except to navigate the team toward a clear goal and provide needed resources and mentoring support.</li><li>Hire people based on alignment of motivation, because that will get them (and you) through almost certain adversity and keep you honest in times of success.</li></ul><p>📣 <strong>If you enjoyed this post please clap 👏 &amp; comment </strong>💬 <strong>to let us know</strong></p><p><em>Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement or recommendation by Alix Ventures, BIOS Community, or its affiliates. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by Alix Ventures employees are those of the employees and do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, and content sponsors.</em></p><h3>Join BIOS Community 🎉</h3><p>Become a member, continue the conversation, connect with like-minded Life Science innovators, access exclusive resources, &amp; invite-only events…</p><p><strong>Apply to Join — </strong><a href="https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform"><strong>Membership Application</strong></a></p><h3>For More Interesting Content 💭</h3><p>🧬 <strong>Podcast</strong> — <a href="https://open.spotify.com/show/2HmcPq9k8fYpn60F3hw6Ra?si=Qk9UeVGUSQajclaTYzN2uQ">Stream Full Episodes</a></p><p>🧪 <strong>YouTube </strong>— <a href="https://www.youtube.com/channel/UCWadRaYPrE1kE4t9LuCd28w">Watch Videos</a></p><p>🩺<strong> Twitter </strong>— <a href="https://twitter.com/bios_community">Explore Feed</a></p><p>🦠 <strong>LinkedIn</strong> — <a href="https://www.linkedin.com/company/bios-community">Read Posts</a></p><h4>Subscribe to BIOS Newsletter for special content: <a href="https://www.bios.community/content">Click Here</a> 🔥</h4><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e7ebcf654d53" width="1" height="1" alt=""><hr><p><a href="https://medium.com/bios-community/founder-spotlight-48-richard-novak-unravel-biosciences-e7ebcf654d53">Founder Spotlight #48: Richard Novak @ Unravel Biosciences</a> was originally published in <a href="https://medium.com/bios-community">BIOS Community</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Founder Spotlight #47: Sean Kevlahan @ Nanite]]></title>
            <link>https://medium.com/bios-community/founder-spotlight-47-sean-kevlahan-nanite-2e505dcaeb1d?source=rss-183f327fce8c------2</link>
            <guid isPermaLink="false">https://medium.com/p/2e505dcaeb1d</guid>
            <category><![CDATA[science]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[entrepreneurship]]></category>
            <category><![CDATA[founders-spotlight]]></category>
            <dc:creator><![CDATA[BIOS]]></dc:creator>
            <pubDate>Tue, 28 Mar 2023 21:04:49 GMT</pubDate>
            <atom:updated>2023-04-10T15:01:17.756Z</atom:updated>
            <content:encoded><![CDATA[<p><a href="https://www.bios.community/"><strong><em>BIOS</em></strong></a><strong><em>: </em></strong><em>Nucleus of Life Science Innovation 🚀</em></p><h4>JOBS</h4><ul><li><strong><em>BIOS Talent: </em></strong><a href="https://medium.com/bios-community/bios-talent-worlds-first-techbio-job-board-weekly-newsletter-7d747d78dfaa"><em>Find Jobs @ Breakout TechBio Companies </em></a><em>— </em><a href="https://jobs.bios.community/companies"><strong><em>Search Jobs</em></strong></a><em> 🚀</em></li><li><strong><em>Post Jobs: </em></strong><em>Add Your Startup to BIOS Talent — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLScR_bLlCQ7Ie6bJ_HZ_dJ_LmuV3TsDEi-aNDC8N9GPz6psk1Q/viewform"><strong><em>Post Now</em></strong></a><strong><em> </em></strong><em>🎉</em></li><li><strong><em>Students:</em></strong><em> </em><a href="https://www.alix.vc/students"><em>Join Alix Ventures Fellowship</em></a><em> — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSckliaB67e-W2o9cmSbRNPLKrBBmtAx_S6CiFufc6QwHSCWSg/viewform"><strong><em>Join Now</em></strong></a><em> 🧬</em></li><li><strong><em>BIOS Contributor:</em></strong><em> </em><a href="https://medium.com/bios-community/write-for-bios-guest-contributor-aff9fbe6e1e"><em>Share Your Thought Leadership</em></a><em> — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSdGPtCdigoAu0ePKvsgcq08qPwRFWkKrHOjIQe7nCP5II_Xeg/viewform"><strong><em>Join Now</em></strong></a><em>🔬</em></li></ul><h4>CONTENT &amp; COMMUNITY</h4><ul><li><strong><em>BIOS Daily:</em></strong><em> Join 25K+ Subscribers Following TechBio — </em><a href="https://www.bios.community/content"><strong><em>Sign Up</em></strong></a><em> 🔥</em></li><li><strong><em>BIOS Insider: </em></strong><em>Premium TechBio Thought Leadership — </em><a href="https://bioscommunity.substack.com/"><strong><em>Sign Up</em></strong></a><strong><em> </em></strong><em>✨</em></li><li><strong><em>BIOS Commons: </em></strong><a href="https://medium.com/bios-community/introducing-bios-fostering-early-stage-healthcare-life-sciences-innovation-78c11dd57fff"><em>World’s Largest #TechBio Community</em></a><em> — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform"><strong><em>Join Now</em></strong></a><strong><em> </em></strong><em>🎉</em></li></ul><h4>INVEST</h4><ul><li><strong><em>BIOS Angels:</em></strong><em> </em><a href="https://medium.com/bios-community/introducing-bios-angels-worlds-1st-techbio-angel-syndicate-5faec24d8439"><em>1st TechBio Angel Investing Syndicate </em></a><em>— </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSe_0k-Ehi2uzTa_geqDm_B9kuRVWNyrvWSU7ch_5hqEKMoahg/viewform"><strong><em>Join Now</em></strong></a><strong><em> </em></strong><em>🌟</em></li><li><strong><em>Alix Limited: </em></strong><em>Invest in Breakout TechBio Startups — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSfqKG3fZOcXTtZTwKEk3wOvN0CyIIUBZkn-FFf5JhRHE1zW0Q/viewform"><strong><em>Learn More</em></strong></a><strong><em> </em></strong><em>🧠</em></li></ul><h3>By:</h3><p><a href="https://www.alix.vc/"><strong><em>Alix Ventures</em></strong></a><strong><em>: </em></strong><em>Supporting Early Stage Life Science Startups Engineering Biology to Drive Radical Advances in Human Health</em></p><p><strong><em>Calling All Innovators </em></strong><em>— </em><a href="/service/mailto:partners@alix.vc"><em>Click to Reach Out</em></a><em> 🚀</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*WWW1G9_QZSz4cBJEGf9KCA.png" /></figure><p><a href="https://www.nanitebio.com/"><strong><em>Nanite</em></strong></a><strong><em> </em></strong><em>is a next-generation non-viral gene delivery company developing a new class of programmable polymer nanoparticles for a range of modalities and indications. We apply cutting-edge high-throughput experimental and machine learning (ML) methods to design fit-for-purpose delivery vehicles across a broad range of genetic cargos. We have built the first comprehensive data-base for how polymers interact in biological systems. With our data, we develop predictive models to understand what polymer nanoparticle chemical features drive in-vivo trafficking, endosomal escape, editing efficiency and expression. Our approach allows for faster development of non-viral delivery vehicles and greatly decreases discovery time for gene therapies.</em></p><p><a href="https://www.linkedin.com/in/sean-kevlahan-46b02721/"><strong><em>Sean Kevlahan</em></strong></a><em> is Co-Founder and CEO of Nanite. Sean has over a decade of experience in the cell and gene therapy market with a wealth of knowledge in product development and building biotechnology businesses. He began his career studying chemical engineering at Northeastern University where he earned his PhD applying novel polymers to interface with biological systems. From his graduate work, he co-founded Quad Technologies which commercialized dissolvable polymer cell culture scaffolds to expand immune cells for CAR-T applications and was later acquired by Bio-Techne. After Quad, Sean was an executive leader at Bio-Techne leading the corporate cell and gene therapy focus and running a multi-million dollar cross-divisional business unit with over 200 products in his business.</em></p><h3>Personal Spark</h3><h4>What prompted you to pursue a career in Life Sciences? Was there a specific moment in time or influence you can remember? What drives you to work in this space?</h4><p>That’s a great question. I haven’t narrowed it down to a single event that made me develop a passion for Life Sciences but I view it as more of a journey. I started out, as many undergrads do, with a general interest in medicine. As part of that journey, you end up taking a lot of fundamental technical courses (biology, chemistry, etc.). I found myself with more of a curiosity about the intersection of chemistry and biology than practicing as a future clinician. I thought to myself that with the combination of the two you could impact the development of next-generation therapeutics. The passion for developing products in life sciences started in graduate school studying chemical engineering. We applied fundamental chemistry and biology understandings to build tangible products. There are very few instances in life where you can imagine building a product that can directly affect someone else’s life in a meaningful way. Graduate chemical engineering allowed me to see that I could do that by developing technologies that could lead to both improvements in current products but by also developing new ones. That is what really gets me up in the morning and feeds my passion to what we are doing at Nanite.</p><h4>How did you get your training to be able to build your company?</h4><p>I didn’t have any formal training in building a company. I didn’t receive an MBA or take any courses to start my first venture, Quad Technologies. I simply bought a couple of books, surrounded myself with advisors that knew more than I did in certain areas, and jumped in with both feet. There were a lot of what I would call “learning experiences” during my first venture and that’s where you really get training! I’ve constantly applied my previous experiences in steering away from what failed and focus on what worked. Applying what you’ve learned is critical for starting any venture and I’ve argued that you learn much more from past failures than your successes.</p><h4>Can you tell us a little bit about your background &amp; career thus far? What were you doing before you started running a high potential venture backed startup?</h4><p>I started graduate school at Northeastern University right after finishing undergrad in Biochemistry. I had a keen interest in moving to more applied science so that’s why I chose Chemical Engineering as my focus for graduate school. I always felt that a lot of science gets left on the bench with no real means of translation to something the world could use. As I dove more into materials science, specifically polymer chemistry, I constantly thought about how polymers interface with biological systems. Those persistent insights drove me to founding my first venture Quad Technologies where we applied material science to grow immune cells for CAR-T applications. That led to significant interest from partners, which in turn led to an acquisition by Bio-Techne. After the acquisition, I helped Bio-Techne nucleate and build their cell and gene therapy business and was leading a team of 70 people by the end of my tenure.</p><h3>Company Overview</h3><h4>What problem is your company solving?</h4><p>Correcting genetic mutations in the human body is tremendously difficult. It is not because we don’t <em>know</em> what we need to do e.g. deliver a gene editor (CRISPR/Cas9) or express a missing protein (e.g. mRNA), but in many cases we simply can’t get the “cargos” to the right place in the human body. Cargos have to be packaged in what we would regard as first-generation vehicles such as viruses which often don’t have the capacity, robustness or safety that patients need. One critical limitation in current viral or non-viral technologies (e.g. lipid nanoparticles) is that the field hasn’t been able to achieve “last-mile delivery” which is cell-specific targeted delivery outside the liver. While there have been advances, the delivery problem remains the major stumbling block to effective gene therapies.</p><h4>Quite simply, what does your company do?</h4><p>The interaction between chemistry and biology in the human body is wildly complex. We are in the delivery business and we start by recognizing that there are a vast number of pathways you can build to get to a particular destination within the body. With that, we apply state-of-the-art artificial intelligence techniques to predict which chemical features will get us to the right place in the body; much like a GPS for your car navigating you to the most optimal routes. In a nutshell, we use artificial intelligence to design delivery vehicles with any cargo and partner with biotechnology companies to build their delivery vehicle with their cargo for a particular genetic disease.</p><h4>Now in more depth, what are the specifics of what your company does?</h4><p>Our proprietary platform — SAYER™ — combines automated polymer synthesis and high-throughput<em> in vivo</em> screening with artificial intelligence to design “programmable” polymer nanoparticles (PNPs) delivering a broad range of genetic cargoes with tissue specificity. We work with genetic medicine biotechnology companies and patient advocacy groups to develop fit-for-purpose delivery vehicles across different indications as part of our delivery-as-a-service (DaaS) partnership model.</p><h4>Why does your solution matter for the world when you get it right?</h4><p>Gene therapy is the next frontier in medicines today. The highest bar to clear has always been how to effectively deliver a genetic payload to the target of interest. Many have done it via viral delivery, but there are some significant limitations such as: costs to manufacture, payload capacity, and immunogenicity. Non-viral delivery can address all of these concerns, allowing for increased cargo capacity and thus creating larger clinical indication opportunities and decreasing costs substantially to truly democratize gene therapies. Design of non-viral delivery vehicles is not intuitive given the near infinite chemical space. Applying AI allows us to explore a near infinite chemical design space without having to empirically test every formulation. What that means is that you can get to a lead delivery vehicle in a much shorter time than a classic discovery process e.g. a random walk approach.</p><h3>Genesis</h3><h4>Tell us about the founding of your company — how did everything come together?</h4><p>Shashi and I met at Northeastern University where he was my academic advisor. Much of the work that we did was applying materials science to solve interesting biological problems. A few years into my graduate work, I met Thomas around the time we were starting Quad Technologies and in which he was our first investor. I’ve stayed in touch with both Shashi and Thomas ever since.</p><p>The founding of Nanite starts as many startups do, a bunch of friends get together and shoot the breeze on what the world will be doing next. Thomas, Shashi, and I are always talking about what novel materials at the intersection of biology could enable and initially, we focused our discussion on the new post-Covid world. Each one of us believed that gene therapy had a delivery problem, that mRNA is a new paradigm, and that the key problem to overcome was the design of delivery vehicles to traffic to different organs in the body. Following our conclusions, I’d argue the most important question that we came up with was: “The polymer universe is huge…where do we even start?”. That was the ah-ha moment. We scoured the literature for who was focused on developing design rules for polymer gene delivery and we found Theresa Reineke’s fantastic work in this field. Shashi reached out to Theresa , we all got together, and as they say the rest is history.</p><h4>Timing is everything — how did you know the timing was right?</h4><p>The mRNA-based Covid-19 vaccines were really the eye opener for non-viral delivery. The unsung hero of these covid vaccines was not the mRNA itself but the delivery vehicle that encapsulates the mRNA. Prior to the vaccine launch, the gene therapy market was inch-wide mile-deep in using AAV as the delivery vehicle of choice. Covid flipped the biotechnology market completely upside down, enabling more transient based therapies. Combining market trends with a delivery need — that was the eye opening moment. We knew that if we could develop a non-viral delivery vehicle with tissue specificity and without cargo limitations, we would unlock the next generation of gene therapies.</p><h3>Accomplishments</h3><h4>What are some of the notable milestones your company has achieved thus far?</h4><ul><li>Our talented technical team has taken our SAYER platform to the next level, have increased our throughput by 10X and decreased our cost per data point substantially. With that, our AI models are producing compelling predictive power and allowing us to explore a universe of different polymer compositions</li><li>We recently closed our seed round led by world class investors, Dylan Reid at Zetta Venture Partners with Enke Bashllari at Arkitekt Ventures joining the round.</li><li>A big part of our strategy is to partner with patient advocacy groups to help build a delivery system for certain gene therapies. The first partnership we closed on is the Charcot-Marie Tooth disease (CMT) which is a monogenic neurodegenerative disease that affects 1 in every 2,500 globally. CMT does not have any viable gene therapy interventions today and the need for inhibiting PMP22 over-expression is critical for ameliorating the pathology. The second patient advocacy relationship we recently closed is the Cystic Fibrosis foundation (CFF). Cystic Fibrosis is a debilitating disease where current treatments cannot fully address the needs of all patients. The goal of the project is to develop a next generation polymer delivery vehicle with mRNA to express CFTR, the misfolded protein in CF patients.</li></ul><h3>Pay It Forward</h3><h4>Throughout the journey, what have been some of your biggest takeaways thus far? What advice/words of wisdom would you share from your story for other founders?</h4><p>The biggest piece of advice that I have in starting a venture is to invest the time to find the right team and investors. In the early days, it starts with a few people on the team which will help build the first prototype or critical pre-clinical data that you need to move the business forward. Hiring the wrong people early on will cause huge distractions and it will take longer to hit your product milestones. That said, take your time hiring your team! Another piece of advice is regarding investors: you need to view them as partners in your business. They provide the fuel that gets you from point A to point B and many times going from A to B is not a straight line. Having investors who understand your space, are willing to help when needed, and understand how to navigate difficult times, is critical. I’ve always said to other founders, just as investors perform due diligence on you, you should be doing your own diligence on them to see if there is a fit. Lastly, make sure you are always speaking to your target customer/partner. Take the time and define what success looks like with the end-user. It’s super important to get your product/service in users hands early to get feedback so that you have the ability to refine.</p><h4>What are some of the must-haves for an early stage Life Sciences startup in your eyes? (Key critical components like team, academic papers, industry know-how, etc.)</h4><p>For any Life Science startup I would say a seminal publication is critical prior to starting your venture. A compelling seminal publication adds a ton of technical credibility. It further allows the ability to share your initial vision publicly enabling commercial feedback to whether you actually have a potential product to commercialize. Following a publication, the next must have is a strong team. I’ve mentioned this numerous times but I can’t stress enough that it’s the team that makes the dream. Industry know-how is helpful but not critical. If you have team members or co-founders with experience in the industry you are planning to tackle, it easily addresses market knowledge gaps, sales-cycle, and product positioning.</p><h4>What are some of the traits that make a great founder? What type of risk profile/archetype does someone need to have to be a founder in your opinion?</h4><p>Grit and bias to action are the top qualities that make a great founder. Regarding grit, there is a ton of uncertainty when starting something new and you make critical assumptions at the beginning which may or may not be correct. A founder must be able to move nimbly in times of uncertainty. On bias to action, founders need to make decisions quickly and at moments of little information. Action inertia can be detrimental to the business and leaves your team with uncertainty.</p><h4>For folks coming out of academia, what advice would you share?</h4><p>The translational bridge from academic work to a commercial product is much larger than you would think. The most common mistake in technology transfer from academia is that there is a big difference between a prototype and a commercial product. Many think that translating intellectual property from their lab to a commercial product is a straightforward development process that can be done in a short amount of time, but it always takes much longer and costs much more than you expect.</p><h4>Not everyone knows everything. Often founders have to learn either the science or the business side better. What advice would you give for someone picking up a new skill set such as this?</h4><p>As a founder and especially a first time founder, there will be a ton of knowledge gaps. My advice is to seek out someone who is experienced in the skill you want to learn. This can provide you with valuable guidance, feedback and support. It’s always helpful to find either mentors or hire experienced leadership that has been part of a startup before. Personally, I’ve always hired against skills that I view as my own knowledge gaps.</p><h4>Can you demystify the process of what it was like to raise VC funding? What were the highlights &amp; low lights? Any advice or words of wisdom for future founders?</h4><p>Before you start raising capital, you need to have a clear and compelling story about the business you are looking to build. That said, you have to hone your storytelling skills. Storytelling is one of the best ways to convey the big picture and why a VC should care about what you are doing. In addition, raising capital is very relationship driven and it takes time to build a relationship with any VC. I always say that raising capital, especially in this environment, will take longer than you would expect. One piece of advice is to invest the time with the VC you want to work with, ideally before you need to start fundraising, make sure they understand the business completely, and do your own diligence on a VC and their firm prior to taking their investment.</p><h4>What advice for managing and hiring a great team can you share?</h4><p>Hiring a great team takes a lot of time and patience. It’s important to hire slowly and do thorough diligence on candidates. This is especially important early on when you are starting out. A players hire A players and you need to make sure you identify and bring those talented individuals into your organization. Also, if you are actively managing your team, you might have the wrong team. A great team are self-starters and will execute with little management. That said, to ensure that dynamic it’s important to paint a clear picture for the vision of the company and near term milestones.</p><p>📣 <strong>If you enjoyed this post please clap 👏 &amp; comment </strong>💬 <strong>to let us know</strong></p><p><em>Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement or recommendation by Alix Ventures, BIOS Community, or its affiliates. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by Alix Ventures employees are those of the employees and do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, and content sponsors.</em></p><h3>Join BIOS Community 🎉</h3><p>Become a member, continue the conversation, connect with like-minded Life Science innovators, access exclusive resources, &amp; invite-only events…</p><p><strong>Apply to Join — </strong><a href="https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform"><strong>Membership Application</strong></a></p><h3>For More Interesting Content 💭</h3><p>🧬 <strong>Podcast</strong> — <a href="https://open.spotify.com/show/2HmcPq9k8fYpn60F3hw6Ra?si=Qk9UeVGUSQajclaTYzN2uQ">Stream Full Episodes</a></p><p>🧪 <strong>YouTube </strong>— <a href="https://www.youtube.com/channel/UCWadRaYPrE1kE4t9LuCd28w">Watch Videos</a></p><p>🩺<strong> Twitter </strong>— <a href="https://twitter.com/bios_community">Explore Feed</a></p><p>🦠 <strong>LinkedIn</strong> — <a href="https://www.linkedin.com/company/bios-community">Read Posts</a></p><h4>Subscribe to BIOS Newsletter for special content: <a href="https://www.bios.community/content">Click Here</a> 🔥</h4><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2e505dcaeb1d" width="1" height="1" alt=""><hr><p><a href="https://medium.com/bios-community/founder-spotlight-47-sean-kevlahan-nanite-2e505dcaeb1d">Founder Spotlight #47: Sean Kevlahan @ Nanite</a> was originally published in <a href="https://medium.com/bios-community">BIOS Community</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Founder Spotlight #46: Adam Margolin @ Flashpoint Therapeutics]]></title>
            <link>https://medium.com/bios-community/founder-spotlight-46-adam-margolin-flashpoint-therapeutics-e3a22805a1de?source=rss-183f327fce8c------2</link>
            <guid isPermaLink="false">https://medium.com/p/e3a22805a1de</guid>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[entrepreneurship]]></category>
            <category><![CDATA[founders-spotlight]]></category>
            <category><![CDATA[biotechnology]]></category>
            <dc:creator><![CDATA[BIOS]]></dc:creator>
            <pubDate>Tue, 28 Mar 2023 20:50:50 GMT</pubDate>
            <atom:updated>2023-03-29T16:07:21.097Z</atom:updated>
            <content:encoded><![CDATA[<p><a href="https://www.bios.community/"><strong><em>BIOS</em></strong></a><strong><em>: </em></strong><em>Nucleus of Life Science Innovation 🚀</em></p><h4>JOBS</h4><ul><li><strong><em>BIOS Talent: </em></strong><a href="https://medium.com/bios-community/bios-talent-worlds-first-techbio-job-board-weekly-newsletter-7d747d78dfaa"><em>Find Jobs @ Breakout TechBio Companies </em></a><em>— </em><a href="https://jobs.bios.community/companies"><strong><em>Search Jobs</em></strong></a><em> 🚀</em></li><li><strong><em>Post Jobs: </em></strong><em>Add Your Startup to BIOS Talent — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLScR_bLlCQ7Ie6bJ_HZ_dJ_LmuV3TsDEi-aNDC8N9GPz6psk1Q/viewform"><strong><em>Post Now</em></strong></a><strong><em> </em></strong><em>🎉</em></li><li><strong><em>Students:</em></strong><em> </em><a href="https://www.alix.vc/students"><em>Join Alix Ventures Fellowship</em></a><em> — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSckliaB67e-W2o9cmSbRNPLKrBBmtAx_S6CiFufc6QwHSCWSg/viewform"><strong><em>Join Now</em></strong></a><em> 🧬</em></li><li><strong><em>BIOS Contributor:</em></strong><em> </em><a href="https://medium.com/bios-community/write-for-bios-guest-contributor-aff9fbe6e1e"><em>Share Your Thought Leadership</em></a><em> — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSdGPtCdigoAu0ePKvsgcq08qPwRFWkKrHOjIQe7nCP5II_Xeg/viewform"><strong><em>Join Now</em></strong></a><em>🔬</em></li></ul><h4>CONTENT &amp; COMMUNITY</h4><ul><li><strong><em>BIOS Daily:</em></strong><em> Join 25K+ Subscribers Following TechBio — </em><a href="https://www.bios.community/content"><strong><em>Sign Up</em></strong></a><em> 🔥</em></li><li><strong><em>BIOS Insider: </em></strong><em>Premium TechBio Thought Leadership — </em><a href="https://bioscommunity.substack.com/"><strong><em>Sign Up</em></strong></a><strong><em> </em></strong><em>✨</em></li><li><strong><em>BIOS Commons: </em></strong><a href="https://medium.com/bios-community/introducing-bios-fostering-early-stage-healthcare-life-sciences-innovation-78c11dd57fff"><em>World’s Largest #TechBio Community</em></a><em> — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform"><strong><em>Join Now</em></strong></a><strong><em> </em></strong><em>🎉</em></li></ul><h4>INVEST</h4><ul><li><strong><em>BIOS Angels:</em></strong><em> </em><a href="https://medium.com/bios-community/introducing-bios-angels-worlds-1st-techbio-angel-syndicate-5faec24d8439"><em>1st TechBio Angel Investing Syndicate </em></a><em>— </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSe_0k-Ehi2uzTa_geqDm_B9kuRVWNyrvWSU7ch_5hqEKMoahg/viewform"><strong><em>Join Now</em></strong></a><strong><em> </em></strong><em>🌟</em></li><li><strong><em>Alix Limited: </em></strong><em>Invest in Breakout TechBio Startups — </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSfqKG3fZOcXTtZTwKEk3wOvN0CyIIUBZkn-FFf5JhRHE1zW0Q/viewform"><strong><em>Learn More</em></strong></a><strong><em> </em></strong><em>🧠</em></li></ul><h3>By:</h3><p><a href="https://www.alix.vc/"><strong><em>Alix Ventures</em></strong></a><strong><em>: </em></strong><em>Supporting Early Stage Life Science Startups Engineering Biology to Drive Radical Advances in Human Health</em></p><p><strong><em>Calling All Innovators </em></strong><em>— </em><a href="/service/mailto:partners@alix.vc"><em>Click to Reach Out</em></a><em> 🚀</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*T6i_UYhC91KbWD_54l2M8g.png" /></figure><p><strong><em>Flashpoint Therapeutics</em></strong><em> will bring to patients a new approach to designing potent cancer immunotherapies that transform therapeutic components from ineffective to curative through optimized nanoscale architecture.</em></p><p><em>Flashpoint nanostructures are all-in-one formulations that kinetically tune and co-deliver precise combinations of therapeutic components with nanoscale presentation optimized to induce powerful, coordinated anti-tumor immune response. This approach overcomes limitations of current technologies that rely on mixing therapeutic components with little control over their co-delivery or structural presentation.</em></p><p><em>Based on in vivo mouse studies, Flashpoint nanostructures yield 35 times increased co-delivery of therapeutic components to immune cells, 80 times stronger immune activation, and 6.5 times greater tumor killing.</em></p><p><em>Across 9 in vivo mouse studies performed to date, spanning different tumor types, Flashpoint immunotherapies have achieved near curative or curative efficacy using the same components that are ineffective in conventional formulations.</em></p><p><em>Flashpoint Therapeutics was created to bring this same benefit to cancer patients.</em></p><p><a href="https://www.linkedin.com/in/adam-margolin-332a196/"><strong><em>Adam Margolin</em></strong></a><em> is Co-founder &amp; CEO @ Flashpoint Therapeutics</em></p><p><em>Adam was previously a Venture Partner @ Khosla Ventures, where he led efforts in therapeutic platform company creation, investment diligence, board level strategic guidance, and executive leadership of a cancer cell therapy company named NextVivo.</em></p><p><em>Over his 20-year academic career, Adam performed highly influential work in computational biology and cancer research and led some of the largest and most successful research organizations in these areas.</em></p><p><em>Adam was Chair and Professor of the Department of Genetics and Genomic Sciences, Director of the Icahn Institute for Data Science and Genomic Technology, and Senior Associate Dean of Precision Medicine at Mount Sinai. In these roles, he led an organization that rose to become the #3 ranked genetics department in the country, encompassing over 700 people and over $100M annual revenue. Concurrently, Adam served as Chief of Data Science of Sema4.</em></p><p><em>Prior to Mount Sinai, Adam was the Founding Director of the Computational Biology program at Oregon Health &amp; Science University, where he was also promoted to the rank of Tenured Full Professor. Previously, Adam was Director of Computational Biology and co-Leader of Strategy at Sage Bionetworks.</em></p><p><em>Adam is an internationally recognized researcher in the fields of computational biology and cancer research and has developed widely used methods that have been ranked among the most influential algorithms in the field.</em></p><p><em>Adam performed his postdoctoral research at the Broad Institute of Harvard and MIT and obtained his PhD. from Columbia University. He also holds a bachelor’s degree from the Wharton School of Business and a master’s degree in Computer Science from the University of Pennsylvania.</em></p><h3>Personal Spark</h3><h4>What prompted you to pursue a career in Life Sciences? Was there a specific moment in time or influence you can remember?</h4><p>After High School, I went to Wharton Business School and worked on Wall Street, because that’s what a kid who likes math does. In the early 2000s breakthroughs in sequencing technologies began generating large amounts of molecular data profiling human disease. I was captivated by the potential of applying the same analytic tools used to predict bond performance to instead predict what drugs will be most effective for a cancer patient.</p><h4>What drives you to work in this space?</h4><p>My mother died of cancer when I was 3. For the past 20 years, my career decisions have been driven by a mission to best contribute to curing cancer.</p><p>I don’t remember my mom and can’t make a conscious link between her suffering and my driving passion to cure cancer. But when my mind chatter is quiet, I look to my north star, which is to advance a cure for cancer through approaches at the frontier of medicine. Following that north star is why I’m building Flashpoint.</p><h4>How did you get your training to be able to build your company?</h4><p>In academia, I had the opportunity to lead organizations up to a scale of 700 people focused on leveraging advanced technologies to accelerate drug discovery. A lot of this experience directly maps to starting a biotech company, particularly in terms of experience with organizational leadership and developing scientific and technical strategies yielding differentiated capabilities.</p><p>I dove into my first company prior to having experience with the nuts and bolts tactical side of biotech in terms of developing a pitch deck, IP strategy, or operational costs and milestones for drug development. I gained experience in these areas by actively focusing on learning them as quickly as possible while building a company.</p><p>For people interested in entrepreneurship, I think it’s OK to have deep experience in some aspects and expect to learn others on the job. Just be willing to embrace this learning actively.</p><h4>Can you tell us a little bit about your background &amp; career thus far? What were you doing before you started running a high potential venture backed startup?</h4><p>I spent about 20 years in academia, gravitating towards a passion for leading interdisciplinary technology-driven programs. I became less interested in promoting my own ideas, and more interested in how we can integrate the best ideas to make a real impact on cancer.</p><p>During this time, I ran my own kind of experiment in studying, applying, and refining strategies for building high performing teams and organizations. I read every book I could find on the inner workings of silicon valley tech companies, dialogued with successful leaders in the industry, put these insights into practice, and refined my personal philosophy and style based on the most effective strategies.</p><p>I was recruited into 3 successive roles with increasing responsibility, ultimately entrusted with leadership over a 500-person organization at Mount Sinai as Chair of the Genetics Department, Director of the Technology Institute, and Senior Associate Dean for Precision Medicine. The leadership philosophy and values I had developed contributed to success at that scale as well, and over 3 years we grew the organization to 700 people, increased revenue by &gt;$20M/year and became the #3 ranked Genetics Department in the US.</p><p>I loved my journey in academia, but ultimately felt I could more directly pursue my north star of working towards curing cancer from the biotech side of the fence. After working for 2 years as a Venture Partner at Khosla Ventures and CEO of a cell therapy company, I’ve indeed felt the opportunity to benefit cancer patients more directly than I could in academia.</p><p>Flashpoint is the most exciting opportunity I’ve seen to bring novel therapies to patients with breakthrough potential, which is why I decided to pursue this mission full-time.</p><p>In academia, I always said my goal was to cure cancer, but there was not really a direct path to do so. Now, I can say our mission in Flashpoint is to cure a cancer patient in 3 years. And I believe we will.</p><h4>Anything else you’d like to share about your life, academic trajectory, etc.?</h4><p>Innovation in the software industry has been enabled by “agile development.” Rather than planning the details of a project over multiple years, long-term objectives are defined at a high level, and the specifics are defined a month at a time.</p><p>I think the agile development concept also applies well to career choices. I’ve never really had a 5-year plan. In fact, it would be a pretty silly plan if I set out to work like crazy for 20 years in academia to achieve the end goals of tenure and large programmatic leadership roles, and then leave to build startups. But all of those choices were the right ones at each time and reflected where my excitement naturally gravitated.</p><p>I think the best companies are run this way as well. For Flashpoint, I have a clear vision of where we want to be in 2 years. I’ve laid out details of how to get there as well, but I think an effective leader should expect the details of any multi-year plan to change and improve as information is gathered during that time. Values and mission should be stable. Tactics should be flexible.</p><h3>Company Overview</h3><h4>What problem is your company solving?</h4><p>We know effective cancer therapy requires co-activating multiple pathways in the same cell. But current drugs just mix together components and cannot control how they work together.</p><p>Flashpoint solves this problem by integrating therapeutic components within nanostructures that control their co-delivery and coordinated activation of the multiple pathways required for the immune system to kill tumors.</p><p>We’ve cured mice with 9 different kinds of tumors using immunotherapies with the same components that are ineffective in conventional formulations. We are working to bring one of these candidates to the clinic.</p><h4>How did you become motivated to tackle this particular problem?</h4><p>The problem I’m motivated to tackle is curing cancer. I spent most of a year thinking about every possible way to pursue that, and converged on leveraging nanotechnology innovations. Most activity in cancer therapeutics centers around improving established modalities, such as cell therapy and antibody mediated immunotherapy. These are good, but they’re saturated, and innovations are incremental.</p><p>So what’s the next frontier? Nanotechnology enables delivery of the right combinations of therapeutic cargo into the right cells, which solves many major limitations of other therapeutics. I think the advantages of nanotechnology rival those of other major therapeutic modalities, but represent a small fraction of investment interest.</p><p>So I set out to build a company that would capitalize on the potential of nanotechnology tools to create more effective combination cancer therapies. The specifics of how to best do that crystalized through discussions with Chad Mirkin about the concept that became Flashpoint.</p><h4>Quite simply, what does your company do?</h4><p>Flashpoint Therapeutics will bring to patients a new approach to designing potent cancer immunotherapies that transform therapeutic components from ineffective to curative through optimized nanoscale architecture. Flashpoint technology represents a key advance in the field of cancer immunotherapy, which requires co-activating multiple pathways to stimulate a coordinated immune response against tumors. Current immunotherapies focus on defining therapeutic components but cannot control how they work together. Flashpoint overcomes this limitation by precisely controlling the components that are co-delivered into single cells and their timing of target activation, enabling coordinated activation of the complex immune response required to kill tumor cells.</p><h4>Now in more depth, what are the specifics of what your company does?</h4><p>Traditional cancer combination immunotherapies are limited because they simply mix together therapeutic components and inject them into patients. These approaches offer little control over the structural presentation of components to immune cells, which is essential for driving anti-tumor efficacy. Structural consideration is also essential to ensure co-delivery of the right combination of molecules at the right time to trigger the multiple pathways that must be co-activated for an effective anti-tumor immune response.</p><p>Leveraging a novel approach, developed in Chad Mirkin’s laboratory over the past 10 years, Flashpoint immunotherapies are all-in-one formulations that kinetically tune and co-deliver multiple components via nanoscale presentation optimized to induce powerful, coordinated anti-tumor immune responses.</p><p>Many formulations we have tested to date combine the ability to induce more potent innate immune stimulation via structurally optimized presentation of oligonucleotides with the ability to direct adaptive immune response against specific tumor antigens co-delivered on our nanostructure surface.</p><p>We have extensively tested this approach in mice, and in all cases Flashpoint formulations transformed ineffective components to yield curative or near curatie efficacy. Flashpoint Therapeutics was created to bring this same benefit to cancer patients.</p><h4>Why does your solution matter for the world when you get it right?</h4><p>A long standing holy grail of cancer immunotherapy has been to induce potent activation of a patient’s own immune defenses against their specific tumor. Approaches to date have not achieved this goal, as approved therapies either induce non-specific immune activation (e.g. checkpoint inhibitors) or attempt to engineer tumor targeting cells outside of the body (e.g. cell therapies), whereas clinical trials attempting to stimulate tumor specific immune activation (e.g. cancer vaccines) have achieved only moderate efficacy.</p><p>We believe Flashpoint solves the missing link that has prevented these approaches from realizing their potential. The key is moving beyond just defining therapeutic components, and defining how they are co-delivered and structurally presented to induce a potent, coordinated anti-tumor immune response.</p><p>We’ve demonstrated this principle in mice — the same components delivered in traditional formulations are ineffective, and are transformed to curative when delivered as Flashpoint nanostructures. If the same advantage is replicated in humans, Flashpoint vaccines will enable highly efficacious treatments that can be delivered safely to patients, developed and manufactured efficiently, and customized to treat virtually any type of cancer.</p><h3>Genesis</h3><h4>Tell us about the founding of your company — how did everything come together?</h4><p>I knew I wanted to build a company in nanotechnology. I thought this was an area of untapped potential in cancer therapeutics. The ability to co-deliver diverse cargo through nanoscale constructs with improved cellular uptake solves many of the challenges that limit current therapeutics.</p><p>Beyond that concept, I needed to listen to the experts. I came in with lots of ideas around nanorobotics, energy activated multimodal theranostics, etc. Technically cool, but impractical. These conversations with experts converged on pursuing a well formulated focus on enabling better co-delivery of precise stoichiometric ratios of cargo into the right cells. Chad Mirkin had the most advanced technology in this arena, which he had been working on for over 10 years, and added key additional dimensions of optimizing the structural presentation of cargo and timing of target activation.</p><p>This rounded out the full picture — nanotechnology enabled therapeutics that precisely control cargo co-delivery and coordinated activation of multiple targets to optimize stimulating the complex immune response required to kill tumor cells.</p><h4>How did you meet your co-founder?</h4><p>I had met Chad peripherally during my academic career. When I was exploring ideas in the nanotech space, it’s hard to throw a stone without hitting Chad, so I reached out to him pretty quickly.</p><p>Chad shared a vision of building a company that could best capitalize on the potential of nanotechnology for cancer therapeutics and had been laying the groundwork to build such a company for the last decade. We were super aligned on vision as well as how to strategically build a platform therapeutics company.</p><p>The ultimate selling point to me was studying around 20 publications that lay the foundation of Flashpoint, and seeing how consistently the key technical advantages were replicated across studies spanning many years, people, tumor models, experimental variations, etc.</p><p>An immense amount of rigorous data supported the conclusions that therapeutics formulated as Flashpoint nanostructures exhibit marked increases in cellular update, immune activation, synchronization of innate and adaptive immunity, tumor killing by T cells, and improved efficacy in vivo.</p><p>As we continued to discuss the concept of Flashpoint, it was clear we had similar views on how to build a company, and this organically led to a mutual decision to dive in as partners in this endeavor.</p><h4>Was there a specific moment when you knew you should pursue this as a business idea? If so, what was it?</h4><p>For me, the decision point was when I was being pushed to explore ideas in other sectors, such as digital health, and my mind kept returning to the potential of building Flashpoint. I think there’s wisdom in where passions naturally direct themselves. So I followed them and took the leap.</p><h3>Accomplishments</h3><h4>What are some of the notable milestones your company has achieved thus far?</h4><p><em>In vivo</em> mouse studies have demonstrated that the Flashpoint approach yields 35 times increased co-delivery of therapeutic components to immune cells, 80 times stronger immune activation, and 6.5 times greater tumor killing.</p><p>Across 9 <em>in vivo</em> mouse studies performed to date, spanning different tumor types, Flashpoint vaccines have achieved near curative or curative efficacy using the same components that are ineffective in conventional formulations.</p><p>A very good summary of our approach was covered in this <a href="https://wgntv.com/news/medical-watch/cancer-vaccines-getting-a-boost-from-science-born-in-chicago/">TV news story</a>. Since our launch, we were also fortunate to be covered in articles in <a href="https://endpts.com/the-field-is-at-a-flashpoint-new-chad-mirkin-founded-biotech-hopes-to-make-more-effective-cancer-vaccines/">endpoints</a>, <a href="https://www.chicagobusiness.com/health-care/cancer-vaccine-being-designed-northwestern-born-nanotech-startup">Crain’s</a>, and <a href="https://www.reuters.com/article/health-rounds/health-rounds-new-vaccine-design-may-improve-effectiveness-idUSL1N34G20R">Reuters</a> and on <a href="https://wgnradio.com/lisa-dent/cancer-vaccines-are-closer-to-becoming-a-reality-in-chicago/">WGN radio</a>. Our technology was recognized by an <a href="https://news.northwestern.edu/stories/2023/01/chad-mirkin-receives-king-faisal-prize-for-work-in-chemistry/">award</a> historically en route to the Nobel Prize.</p><p>We’ve secured broad IP rights reflected in 13 patents.</p><p>In addition to our founders, our team brings prior experience as the President of Takeda (Mark Booth) and winning lawyer in the CRISPR case (Ray Nimrod).</p><p>We’ve charted a strategy to move our first candidate down a clinical development path and to leverage the modularity of our platform to rapidly expand our pipeline through internal programs and partnerships. We are now raising our first institutional funding round to hit the ground running in these directions.</p><h4>What are some of the biggest hurdles ahead? How do these create points of value inflection?</h4><p>We’re laser focused on getting drugs to patients. It will be hard work, but there’s not much technical risk in getting to clinical stage. At that point, any clinical stage company faces risks associated with readouts from first-in-human studies. The data I have seen give me confidence that our initial trial has a high likelihood of demonstrating clinical efficacy, but this is always a risk until clinical readouts are obtained.</p><p>Strategically, one priority I have from the outset is to keep a long-term view of maximizing the potential of the platform, and to not turn a platform therapeutics company into a single asset company. We will need to keep this strategic focus while navigating immediate pressures to focus on short term priorities, which are important but not the full picture.</p><p>Beyond that, we need the essential nuts and bolts pieces of sufficient capital to execute towards our milestones, engaging the right strategic partnerships with pharma companies, recruiting top people at every level, and maintaining cultural and strategic alignment to execute on our mission.</p><h3>Pay It Forward</h3><h4>Throughout the journey, what have been some of your biggest takeaways thus far? What advice/words of wisdom would you share from your story for other founders?</h4><p>I mentioned that when my mind naturally kept returning to the idea of Flashpoint, I took that as a sign to follow that cue. There are times when your excitement just naturally directs itself in a certain direction. That’s the wisest guide to follow.</p><h4>What are some of the must-haves for an early stage Life Sciences startup in your eyes? (Key critical components like team, academic papers, industry know-how, etc.)</h4><p>Personally, I look for approaches that are technologically differentiated from the field and have robust data establishing their advantage in areas of importance. Such technology advantages are necessarily encoded in publications and patents, which are requirements, but I would dig into these with a view of establishing the differentiated aspects and market or clinical need.</p><p>Beyond that, the team is critical. It’s essential to engage people with the right experience, drive, shared values, and chemistry. How to do that can take various forms. If you can put this together from the outset, that’s great. If you’re a killer CEO with a killer founder, it’s often best to try to raise initial cash with a plan of recruiting a killer team from there.</p><h4>What are some of the traits that make a great founder? What type of risk profile/archetype does someone need to have to be a founder in your opinion?</h4><p>You have to be stupid.</p><p>One time I was meditating in a Zen monastery during an intensive week-long retreat. When the master spoke on the last day, I expected he would praise how much progress we made for our effort. Instead, he gave a story of 2 frogs stuck in a vat of boiling milk. One frog was smart. He tried every possible way to escape. It was impossible. So he gave up and drowned. The other frog was stupid. He just kept kicking and kicking and kicking indefinitely, until he churned the milk into butter and jumped out.</p><p>I really hated that story. But a founder needs to be a stupid frog sometimes.</p><h4>For folks coming out of academia, what advice would you share?</h4><p>If I was an AI chatbot programmed to say the most rote answer, it would probably be “follow your passions”. But I’ll say that anyway. If you are drawn to focusing on hard core science, go do that — I did for 20 years. If you’re drawn towards the industry side, go do that. If you want a comfortable 9–5 job with well-defined parameters, go do that. Don’t worry as much about where these will lead in 10 years. Nobody knows. But if you enjoy it, any choice is more likely to lead somewhere good.</p><h4>Not everyone knows everything. Often founders have to learn either the science or the business side better. What advice would you give for someone picking up a new skill set such as this?</h4><p>I’m biased on this question. I spent my career in the deep rabbit holes of science and then picked up the industry side. The industry side is important, but my perspective is that a lot of this can be learned over the course of a few years, whereas science requires a substantially longer training period. I think it would be difficult to devote enough focus to the scientific side without an exclusively dedicated period of time. At least a PhD, advisably a postdoc, possibly additional time in academia. Maybe not staying in academia until tenure then jumping ship like I did — that’s a little silly.</p><p>I’ll hedge this perspective by noting that a foundational quality of a good leader is being able to engage the right people and really listen to them. A founder who’s really good at this, but lacks the scientific side, can certainly be successful.</p><h4>Can you demystify the process of what it was like to raise VC funding? What were the highlights &amp; low lights? Any advice or words of wisdom for future founders?</h4><p>We’re actively in the process for Flashpoint, so may need to update this entry in a few months, though I can also share perspectives from my last fundraise.</p><p>First, prepare your materials, presentation, team, and plans as best as you can. As a mental model, when you get rejections, make sure you don’t have regrets that you left anything on the table in terms of being underprepared. There’s a lot you can’t control. Expect that until you’ve cured every cancer patient on the planet, investors will want more data, more derisking, etc. Don’t fake what you don’t have. But do everything you can with what you do have.</p><p>From there, it’s generally like being the stupid frog I described above. If you are expecting to email a few VCs and get a $10M check, this isn’t the right game. Prepare to take 6 months or a year and just persist in your vision and keep kicking the milk and not look down to see if any of it is turning into butter until then.</p><h4>What advice for managing and hiring a great team can you share?</h4><p>Focus as much on the human aspect as the technical aspect. You definitely need people who are well qualified, but don’t make that the full picture. I would sacrifice specific areas of experience for culture fit any day.</p><p>I have a specific set of values for organizational culture that are important to me, which I codify in my personal set of 6 core values. These are to always put the patient first, simplify, focus, share openly, value contributions over politics, work synergistically, and deliver results. I actively look for people who share these values. It’s good to have diverse opinions in pretty much everything, but not values. I would be clear on what values are important to you and build around those. The people I select for in terms of culture fit will be different from the people that fit with other organizational cultures. But I think it’s important to have a clear vision of the culture you want and select people who align with that vision.</p><h4>Anything else you would like to add? Company, personal, etc.</h4><p>To build successful companies, I think 2 things should be intransient from the outset — mission and culture.</p><p>Since this spotlight is being published at the very early stages of Flashpoint, I’d like to memorialize the mission and culture that will guide our journey over the next few years. In doing so, I invite anyone to hold us to these commitments and to call us out if we deviate from them.</p><p>Our mission is to demonstrate benefit to cancer patients. By 2026, I want to know the name of a cancer patient who is living because of a cancer drug we have made for them. By 2028, I want to scale the platform to benefit as many patients as we can.</p><p>Our culture will enable this mission by prioritizing what’s good for patients above all, and working as a synergistic, open, apolitical team focused on the goal of rapidly bringing to patients the most effective therapies enabled by our platform.</p><p>All of our tactics will change and evolve, but our core mission and culture will not change. That’s a commitment made in this document so anyone can hold us to it. If you share this vision and would be interested in participating in our mission please feel free to contact me at adam@flashpoint.bio.</p><p>📣 <strong>If you enjoyed this post please clap 👏 &amp; comment </strong>💬 <strong>to let us know</strong></p><p><em>Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement or recommendation by Alix Ventures, BIOS Community, or its affiliates. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by Alix Ventures employees are those of the employees and do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, and content sponsors.</em></p><h3>Join BIOS Community 🎉</h3><p>Become a member, continue the conversation, connect with like-minded Life Science innovators, access exclusive resources, &amp; invite-only events…</p><p><strong>Apply to Join — </strong><a href="https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform"><strong>Membership Application</strong></a></p><h3>For More Interesting Content 💭</h3><p>🧬 <strong>Podcast</strong> — <a href="https://open.spotify.com/show/2HmcPq9k8fYpn60F3hw6Ra?si=Qk9UeVGUSQajclaTYzN2uQ">Stream Full Episodes</a></p><p>🧪 <strong>YouTube </strong>— <a href="https://www.youtube.com/channel/UCWadRaYPrE1kE4t9LuCd28w">Watch Videos</a></p><p>🩺<strong> Twitter </strong>— <a href="https://twitter.com/bios_community">Explore Feed</a></p><p>🦠 <strong>LinkedIn</strong> — <a href="https://www.linkedin.com/company/bios-community">Read Posts</a></p><h4>Subscribe to BIOS Newsletter for special content: <a href="https://www.bios.community/content">Click Here</a> 🔥</h4><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e3a22805a1de" width="1" height="1" alt=""><hr><p><a href="https://medium.com/bios-community/founder-spotlight-46-adam-margolin-flashpoint-therapeutics-e3a22805a1de">Founder Spotlight #46: Adam Margolin @ Flashpoint Therapeutics</a> was originally published in <a href="https://medium.com/bios-community">BIOS Community</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>